

Department of Defense
Dept. of the Army -- USAMRAA
DoD Neurofibromatosis Clinical Trial Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-CTA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$1,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Clinical Trial Award (CTA) mechanism was created in FY99. Since then, 18 Clinical Trial Award proposals have been received, and 3 have been recommended for funding. The NFRP Clinical Trial Award supports clinical research with the potential to have a major impact on the treatment and/or management of neurofibromatosis and/or Schwannomatosis. Funding from this award mechanism cannot be used for preclinical research studies. Clinical Trial Awards will support Phase 0, Phase I, and Phase II clinical trials (please refer to <http://www.clinicaltrials.gov> and www.fda.gov/cder/guidance/6384dft.htm for descriptions of each type of clinical trial). Applicants must clearly specify in their proposals which type of clinical trial is being proposed: Phase 0, Phase I, or Phase II. Each proposal should contain only one clinical trial with a distinct study design. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is

required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. If the trial is multi-institutional, applicants should include plans for communication and real-time data transfer between the collaborating institutions as well as how specimens and/or imaging products obtained during the study will be handled in the appropriate sections of the Clinical Protocol. An intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials as part of the Supporting Documentation. Important aspects of the Clinical Trial Award are as follows:

- The proposal must include a named study coordinator who will guide the clinical protocol through Institutional Review Board (IRB), Human Subjects Research Review Board (HSRRB), and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual.
- IRB approvals should be in process or completed before submission of the proposal to the Clinical Trial Award mechanism.
- The results of the clinical trial should have a clear and important impact.
- The clinical trial must have clearly defined and appropriate endpoints.
- The PI must demonstrate availability of and access to an appropriate patient population that will support a meaningful outcome for the study.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16779>

Department of Defense
 Dept. of the Army -- USAMRAA
 DoD Neurofibromatosis Investigator-Initiated Research Award Grant

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-IIRA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 11, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$3,000,000
Award Ceiling:	
Award Floor:	

CFDA Number: 12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding. The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over today's approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3) enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:

- Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;
- Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;
- Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
- Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:

- The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.
- If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.
- The collaborator must be at or above the level of Assistant Professor (or equivalent).

At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16780>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Neurofibromatosis New Investigator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-NIA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$1,350,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP New Investigator Award mechanism (NIA) was created in FY99. Since then, 150 New Investigator Award proposals have been received, and 34 have been recommended for funding. The intent of the NFRP New Investigator Award is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Eligible Principal Investigators (PIs) must be at or below the level of Assistant Professor (or equivalent), must have received no more than \$300K in direct costs for NF research as a PI of a federally funded, non-mentored peer reviewed grant, and must have not received a NIA from any CDMRP program previously.

Experience in NF research is allowed, but not required. However, PIs with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. NIA proposals must include preliminary data relevant to NF and the proposed project. The FY08 NFRP encourages proposals that specifically address critical needs of the NF Community in the following areas: • Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; • Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; • Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; • Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials. Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborator and address the following requirements: • The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without their involvement. • If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history. • The collaborator must be at or above the level of Assistant Professor (or equivalent). • At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16781>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Neurofibromatosis Exploration – Hypothesis Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-EHDA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008

Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$350,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Exploration – Hypothesis Development Award (EHDA) mechanism is being offered for the first time in FY08. The NFRP Exploration – Hypothesis Development Award supports the initial exploration of innovative, untested, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or it should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. Some gaps in supporting rationale may exist due to a lack of available information. The presentation of preliminary data is encouraged, but not required. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b). Studies that do not qualify for exempt or expedited status during review at any level will be administratively withdrawn and will not be funded. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas: • Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; • Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; • Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; • Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Link to Full Announcement

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-IDA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	55
Estimated Total Program Funding:	\$31,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Idea Development Award mechanism was introduced in FY97. Since then, 4,330 proposals have been received and 831 have been recommended for funding. The Idea Development Award supports innovative, high-risk/high-gain approaches to prostate cancer research. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. NEW FOR FY08: Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Important aspects of the Idea Development Award are as follows: 1. Innovation: Innovative research may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the

responsibility of the PI to clearly and explicitly articulate how the proposed research is innovative. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this mechanism. 2. Impact: Research that has high impact will, if successful, significantly advance current methods and concepts for the prevention, detection, diagnosis, or treatment of human prostate cancer. It is the responsibility of the PI to clearly and explicitly articulate the potential impact the proposed research will have on human prostate cancer. 3. Preliminary Data: NEW FOR FY08: Submission of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Although groundbreaking research often involves a degree of risk due to unforeseen difficulties or results, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16804>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer New Investigator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-NIA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	23
Estimated Total Program Funding:	\$7,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP New Investigator Award mechanism was introduced in FY99. Since then, 1,678 proposals have been received and 365 have been recommended for funding. The New Investigator Award supports independent PIs in the early stages of their careers. The PCRP seeks PIs who have innovative, high-impact ideas or new technologies applicable to prostate cancer research, prevention, detection, diagnosis, or treatment. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Important aspects of the New Investigator Award are as follows: 1. Personnel: The PI and collaborator are emphasized in this award. The PI's record of accomplishment will be evaluated regarding his or her potential for contributing to the prostate cancer research field. The PI and collaborator together will be emphasized in peer review to determine whether their combined background and prostate cancer-related expertise demonstrate the ability to accomplish the proposed work. 2. Innovation: Innovative research may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the responsibility of the PI to clearly and explicitly articulate how the proposed research is innovative. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this mechanism. 3. Impact: Research that has high impact will, if successful, significantly advance current methods and concepts for the prevention, detection, diagnosis, or treatment of human prostate cancer. It is the responsibility of the PI to clearly and explicitly articulate the potential impact the proposed research will have on human prostate cancer. 4. Collaborator: Submission to this award mechanism requires a collaborator (or collaborators), appropriate to the proposal, who has experience in prostate cancer research, as demonstrated by a record of funding and publications in prostate cancer research. 5. Preliminary Data: To encourage submissions from PIs early in their careers, proposals are not required to have preliminary data. Although groundbreaking research often involves a degree of risk due to unforeseen difficulties or results, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16805>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Physician Research Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-PRTA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	8
Estimated Total Program Funding:	\$4,700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Physician Research Training Award was introduced in FY03. Since then, 82 proposals have been received and 32 have been recommended for funding. The Physician Research Training Award supports a mentored training experience to prepare physicians with clinical duties and/or responsibilities for a productive career in prostate cancer research. The PI must be in the last year of an accredited medical residency or medical fellowship program, or within the first 3 years following his or her appointment as an Instructor, Assistant Professor, or equivalent. A training program appropriate to the area of study, which may include coursework and seminars, that will provide the PI with experience in key areas such as statistics, bioethics, and/or relevant basic science disciplines, must be part of the application. This award requires the involvement of a designated mentor with an established research program in prostate cancer. Funds from this award are intended to provide aggressive protection, at least 40%, of the PI's time for research. The PI must demonstrate a commitment to a career in prostate cancer research and clinical practice. In addition, up to 50% of a key support person's salary may be provided by this award. Up to \$10,000 in funds per year from this award may be used for research supplies, equipment, and travel to

scientific/technical meetings. These funds may be used for research with laboratory animals and human biological substances, as well as research with human subjects that does not involve clinical trials. PIs may participate in clinical trials as part of their training for this award, but funding for the clinical trials must come from a source other than this award. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16807>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Innovator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-INNOV
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$6,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Innovator Award was first offered in FY01. Since that time, 176 Innovator Award proposals have been received and 16 have been recommended for funding. The Innovator Award supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to, breast cancer. These individuals will have the most potential for future ground breaking achievements in breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could ultimately lead to the eradication of breast cancer. Individuals may be from diverse organizations including, but not limited to, academic institutions, advocacy groups, government agencies, the private sector, the media, and/or professional societies. Since the intent of the Innovator Award mechanism is to recognize creative and innovative individuals rather than projects, the central feature of the award is the innovative contribution that the recipient can make to the eradication of breast cancer. As such, an individual selected to submit a full proposal is required to submit an essay addressing his or her area(s) of focus and how he or she will use the award to pursue his or her most creative vision in breast cancer research. The primary criteria for making these awards will be an individual's past record of creativity, their promise for continued innovation in future work, and an indication of how this award will create and further innovative strategies to solve the breast cancer problem. Experience in breast cancer research is not required; however, the proposal must focus on breast cancer and it is expected that the recipient will commit a minimum of 50% of his or her full-time professional effort to breast cancer research during the tenure of this award.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16808>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-PCTA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	

Expected Number of Awards: 31
Estimated Total Program Funding: \$3,400,000
Award Ceiling:
Award Floor:
CFDA Number: 12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Prostate Cancer Training Award was introduced in FY06. Since then, 271 proposals have been received and 118 have been recommended for funding. The Prostate Cancer Training Award supports training opportunities focused on prostate cancer research or patient care for individuals in the early stages of their careers. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer research. All Prostate Cancer Training Award proposals are to be written with appropriate direction from the mentor and signed by the trainee as the PI and author of the proposal. PIs may apply for predoctoral and postdoctoral traineeships through this award mechanism.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16809>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Impact Award Grant

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-08-BCRP-IMPT
Opportunity Category: Discretionary
Posted Date: Feb 07, 2008
Creation Date: Feb 07, 2008
Original Closing Date for Applications: May 07, 2008
Current Closing Date for Applications: May 07, 2008

Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Impact Award mechanism was first offered in FY07. Since that time, 86 Impact Awards proposals have been received and none have been recommended for funding. The Impact Award supports unique projects or ideas (from small- to large-scale) that possess strong potential to have an unprecedented impact in breast cancer. The most important aspect of this mechanism is the potential of the proposed work to have an extraordinarily high impact and contribute significantly to the goal of eradicating breast cancer. The potential impact may be scientific or clinical and may be near-term or long-term. The proposed work may be from any discipline or combination of disciplines and must be based on a solid overall research strategy. The BCRP seeks proposals from all areas of basic, translational, clinical, behavioral, and epidemiological research. The Impact Award mechanism particularly encourages proposals from underdeveloped and/or underexplored topic areas. Proposals are expected to present ideas that are above and beyond those that fit current award mechanisms offered by the BCRP.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16811>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-IDA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$2,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Idea Development Award mechanism was offered in FY02 through FY06 to support innovative research in ovarian cancer. During this time, 616 proposals have been received and 51 OCRP Idea Development Awards have been made. The OCRP Idea Development Award supports high impact, innovative research that will drive the field forward. NEW FOR FY08 – This award seeks proposals from all areas of ovarian cancer research. However, for FY08, this award encourages proposals that address critical needs of the ovarian cancer community in the following areas: • Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. Important aspects of the Idea Development Award are as follows: 1. Impact: The proposed research should have a significant impact on the concepts or methods that drive the field of ovarian cancer research. The proposed research is expected to make original and important contributions to the goal of advancing ovarian cancer research and/or ovarian cancer patient care. 2. Innovation:

Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. Examples of research that are not innovative and that will not be considered for funding under this mechanism include: Exploring a previously tested hypothesis in a different cell line; using a published series of in vitro assays to further characterize a model system; and incorporating known biomarkers into in vitro or clinical models of ovarian cancer. 3. Preliminary Data: Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. 4. Proposals Involving Clinical Trials: If a proposal requests support for a clinical trial, the PI is required to submit a clinical protocol in addition to the proposal by the proposal receipt deadline. Such trials must have a clinical coordinator who has sufficient time dedicated to the project to carry out the record keeping, coordination, and/or other administrative duties the project entails. The protocol will be reviewed separately. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. 5. Optional Non-traditional Collaboration (NEW FOR FY08): The FY08 OCRP Idea Development Award strongly supports collaborative research between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional collaboration is to increase the leveraging of resources in the ovarian cancer research community. The collaborator in this optional non-traditional collaboration must contribute at least 10% level of effort to the project (as reflected in the budget) and provide intellectual input and research resources (e.g., supplies, reagents, equipment, personnel), or intellectual input and financial resources. Collaborations that bring new perspectives from other disciplines or bring new investigators into the ovarian cancer field are also strongly encouraged. Consequently, if the PI does not have experience in ovarian cancer, then the collaborator must have ovarian cancer experience, as demonstrated through publications in the field, funding history, and/or patient care.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16813>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Translational Research Partnership Grant

This Program Announcement is modified to incorporate a new revised application package.
PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION

PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded).

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-TRP
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$2,500,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Translational Research Partnership Award was first offered in FY07 to support partnerships between clinicians and laboratory scientists to conduct translational research in ovarian cancer. During this time, 22 proposals were received for the Translational Research Partnership Award, and 5 were recommended for funding. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that accelerate the movement of promising ideas in ovarian cancer into clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in ovarian cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a laboratory scientist and the other must be a clinician, and

it should be clear that both have had equal intellectual input into the design of the research project. At least one member of the partnership must have experience either in ovarian cancer research or ovarian cancer patient care. Historically Black College and Universities/Minority Institutions are encouraged to apply. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into the clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. Developing the research plan must involve a reciprocal flow of ideas and information within the partnership. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at (<http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals>). These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Translational Research Partnership Award does not support clinical trials, but may support correlative studies that are associated with an existing clinical trial and projects that develop clinical endpoints for clinical trials. Research projects may also include preclinical studies in animal models and human subjects and human anatomical substances. This award is intended to support both new and established scientists across a broad spectrum of disciplines in research projects that are likely to make a major impact on ovarian cancer. NEW FOR FY08 – The Translational Research Partnership award accepts proposals from all areas of research, but encourages research from these Areas of Encouragement: • Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. This award mechanism is not intended to support the study of new combinations of conventional ovarian cancer therapies. The use of existing resources is encouraged, including libraries of compounds or probes, tissue repositories such as those managed by the Gynecologic Oncology Group, and other existing sets of tissue, blood, or images. Important aspects of the Translational Research Partnership Award are as follows: 1. Partnership: The success of the project depends on the unique skills and contributions of each partner. • Optional Non-traditional Partnership (NEW FOR FY08): This award encourages a partnership between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional partnership is to leverage resources in the ovarian cancer research community. It is expected that in addition to providing intellectual input, the optional non-traditional partnership will contribute research resources (e.g., supplies, reagents, equipment, personnel) and/or financial resources. 2. Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas in ovarian cancer into clinical applications. 3. Preliminary Data: Preliminary data to support

the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in ovarian cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16815>

Department of Defense
Air Force Office of Scientific Research
Research Interests of the Air Force Office of Scientific Research Modification 3

Description of Modification

This BAA has been superseded by AFOSR-BAA-2008-1.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	AFOSR-BAA-2007-1
Opportunity Category:	Discretionary
Posted Date:	Sep 30, 2006
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	This announcement is AFOSR BAA 2007-1 and supersedes AFOSR BAA 2006-1. This announcement is open-ended until revised and should be referenced on all responses.
Current Closing Date for Applications:	This announcement is AFOSR BAA 2007-1 and supersedes AFOSR BAA 2006-1. This announcement is open-ended until revised and should be referenced on all responses.
Archive Date:	Feb 07, 2008
Funding Instrument Type:	Cooperative Agreement Grant Procurement Contract
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	
Estimated Total Program Funding:	
Award Ceiling:	
Award Floor:	
CFDA Number:	12.800 -- Air Force Defense Research Sciences Program
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Additional Information on Eligibility:

All responsible, potential applicants from academia and industry are eligible to submit proposals. AFOSR particularly encourages proposals from small businesses, historically black colleges and universities, minority institutions and minority researchers. However, no portion of this BAA is set aside for a specific group.

Description

AFOSR plans, coordinates, and executes the Air Force Research Laboratory's (AFRL) basic research program in response to technical guidance from AFRL and requirements of the Air Force; fosters, supports, and conducts research within Air Force, university, and industry laboratories; and ensures transition of research results to support USAF needs. The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in three scientific directorates: Aerospace and Materials Sciences, Physics and Electronics, and Mathematics, Information and Life Sciences. If the Full Announcement Link is not available on this synopsis, the FULL ANNOUNCEMENT is available on the Grants.gov website by scrolling to the top of the synopsis page and clicking on the "FULL ANNOUNCEMENT" box surrounded by the dotted line.

Link to Full Announcement

[FULL ANNOUNCEMENT AFOSR-BAA-2007-1
http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opld=11104](http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opld=11104)

Department of Defense
Office of Naval Research
Naval Research Laboratory
NRL Wide Broad Agency Announcement BAA-07-01
Modification 4

Description of Modification

This opportunity is modified by revising topic BAA 57-07-03, Shipboard Electronic Warfare. The Surface Electronic Warfare Systems Branch (SEWS) is interested in design concepts that will incorporate advanced technology in the development and demonstration of a prototype Electronic Warfare (EW) system for shipboard application. NRL is looking to fund multiple proposals beginning FY09 under this BAA for prototype EW systems and or subsystems. An industry day to provide additional classified information will be held at NRL on 5 March 2008. Attendance will be limited to three representatives per company. NRL will request proposals based on white papers submitted in response to this BAA and received by 10 April 2008.

Names of persons attending and their security clearance need to be submitted to NRL by 27 February 2008. The POC for submitting visit requests and clearances is Ms. Helen Crosby, voice: 202-767-5931, fax: 202-404-7690, email: Helen.crosby@nrl.navy.mil. The revised topic as well as the complete BAA including proposal preparation instructions, technical points of contact for each topic, and evaluation criteria is available at <http://heron.nrl.navy.mil/contracts/0708baa/baa.htm>

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	NRLBAA-07-01
Opportunity Category:	Discretionary
Posted Date:	May 11, 2007
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Dec 31, 2008
Current Closing Date for Applications:	Dec 31, 2008
Archive Date:	Dec 31, 2009
Funding Instrument Type:	Grant
Category of Funding Activity:	Science and Technology and other Research and Development
CFDA Number:	12.300 -- Basic and Applied Scientific Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Others

Link to Full Announcement

[NRL Wide Broad Agency Announcement BAA-07-01](http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=13884)
<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=13884>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Era of Hope Scholar Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-EOHS
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant

Category of Funding Activity:	Cooperative Agreement Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Era of Hope Scholar Award mechanism was first offered in FY04. Since that time, 112 Era of Hope Scholar Award proposals have been received and 23 have been recommended for funding. The Era of Hope Scholar Award supports individuals who have high potential for innovation in breast cancer research early in their careers. Nominees for this award should be exceptionally talented, early-career scientists who have demonstrated that they are the "best and brightest" in their field(s) through extraordinary creativity, vision, and productivity. They also should exhibit strong potential for leadership in the breast cancer research community and be able to articulate a vision for the eradication of breast cancer. Individuals should challenge current dogma and demonstrate an ability to look beyond tradition and convention. The Era of Hope Scholar Award proposal must focus on the PI's record of creative and original accomplishments, potential for leadership in the breast cancer research community, and vision for eradicating breast cancer. These aspects of the proposal will receive greater emphasis in the review process than the proposed research project, although the proposed research project also will be considered. Experience in breast cancer research is not required; however, the proposal must focus on breast cancer research and the PI must commit at least 50% of his or her full-time professional effort during the award period to breast cancer research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16794>

DOD Breast Cancer Era of Hope Postdoctoral Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-EHPA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	14
Estimated Total Program Funding:	\$5,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Era of Hope Postdoctoral Award mechanism was first offered in FY06. Since that time, 44 Era of Hope Postdoctoral Award proposals have been received and 16 have been recommended for funding. The Era of Hope Postdoctoral Award supports exceptionally talented recent doctoral graduates who possess both the ambition and the ability to pursue highly innovative breast cancer research during their postdoctoral training. Research proposed for funding by the Era of Hope Postdoctoral Award mechanism should challenge current scientific dogma and demonstrate that the applicant has an ability to look beyond tradition and convention. Award recipients will be expected to challenge the status quo through creative, high-risk, potentially high-gain research that ultimately may lead to the eradication of breast cancer. Candidates for this award should exhibit a strong desire to pursue a career in breast cancer research. Candidates should provide evidence that they are the "best and brightest" among their peers. Proposals must provide evidence of the candidate's potential for success in pursuing innovative research based on his or her qualifications,

characteristics, achievements, and letters of recommendation. Under this award mechanism, the postdoctoral trainee is considered the Principal Investigator (PI) and, as such, should write the project narrative with appropriate direction from the mentor. While the PI is not required to have previous experience in breast cancer research, this research proposal must focus on breast cancer research. The mentor must possess the appropriate expertise in breast cancer, have current peer reviewed breast cancer funding, and clearly demonstrate a commitment to guiding the PI's research and training. The proposed research must be clearly outlined and the innovative nature of the planned research project and/or training must be explicitly stated. Proposals with a multidisciplinary research approach to breast cancer are highly encouraged but not required. The proposal should include information about the mentor's experience in conducting innovative research and how he or she intends to support the PI's innovative breast cancer research endeavors. Proposals involving clinical trials do not meet the intent of this award mechanism. Proposals must provide details on the suitability of the PI's overall training plan for attaining the goals of this mechanism. In addition, proposals must elaborate on the training environment in which the candidate will work and how it will facilitate the candidate's career development as an innovator at the forefront of breast cancer research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16795>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Breast Cancer Clinical Translational Research Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-CTR
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$75,000,000
Award Ceiling:	
Award Floor:	

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Clinical Translational Research (CTR) Award mechanism was first introduced in FY97. Since that time, 216 Clinical Translational Research Award proposals have been received and 40 have been recommended for funding. The CTR Award is intended to promote substantial improvements over current approaches to breast cancer chemoprevention and therapy, including predictive biomarker studies that would better align treatment options with more specific breast cancer subtypes and/or may identify a new way to treat breast cancer patients. These awards are intended to support research projects that are likely to have a major impact on breast cancer by applying promising research findings to the treatment of patients with, or populations at risk for, breast cancer. Principal Investigators (PIs) may have originated projects in their laboratories that will form the basis for translational research leading to clinical trials to be conducted during this award period. Alternatively, PIs may leverage partnerships with industry (if the ability to conduct the required translational research and early phase clinical trial can be demonstrated). Proposals must include preliminary data and a solid rationale to support the feasibility of innovative translational research leading to a prospective clinical trial or study during the course of the award. Proposals also must include a clear experimental plan and a properly powered statistical plan to perform a prospective clinical trial. Investigators must demonstrate availability of and access to an appropriate patient population that will support a meaningful outcome for the study. Proposals addressing predictive biomarker studies must be supported by a previous, retrospective study and must include data validating the methods for the collection, storage, annotation, and analysis of human biological substances.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16799>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Idea Award Grant

Document Type:

Grants Notice

Funding Opportunity Number:	W81XWH-08-BCRP-IDEA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	60
Estimated Total Program Funding:	\$35,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Idea Award mechanism was first offered in FY93. Since that time, 12,797 Idea Award proposals have been received and 1,809 have been recommended for funding. The Idea Award supports highly innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer. The BCRP seeks proposals from all areas of basic, translational, clinical, behavioral, and epidemiological research. The Idea Award is designed to promote new ideas; therefore, proposals need not include preliminary data. Innovation and Impact are the most important aspects of the Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that are not innovative, and will not be considered for funding under this mechanism include: • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. • Investigating the next logical step or incremental advancement of published data.

Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16800>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Synergistic Idea Award Grant

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded). In addition, this modification corrects the Helpdesk e-mail address in the application package to read cdmrp.pa@amedd.army.mil.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-SIA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	25
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Synergistic Idea Award mechanism was first offered in FY06. Since that time, 718 Synergistic Idea Award proposals have been received and 58 have been recommended for funding. The Synergistic Idea Award supports collaborations between two independent investigators who address an innovative, high-risk, potentially high-reward breast cancer research question from synergistic and complementary perspectives. The Synergistic Idea Award is designed to promote new ideas and new collaborations. Proposals are not required to include preliminary data, but a rationale for the work must be provided. Proposals should have a high probability of revealing new avenues of investigation. The Synergistic Idea Award requires the submission of a single proposal that addresses a critical issue in breast cancer research. Proposals must clearly identify the synergy that will enable or greatly accelerate the evaluation of a single innovative hypothesis. The BCRP seeks proposals from all areas of laboratory clinical, behavioral, and epidemiological research. Multi-institutional and/or multidisciplinary proposals are encouraged but not required. Collaborators not from distinct disciplines must clearly explain why the proposed research is synergistic. Innovation, synergy, and impact are important aspects of the Synergistic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that is not innovative and will not be considered for funding under this award mechanism include: • Investigating the next logical step or incremental advancement of published data. • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. Synergy: Research combinations demonstrating synergy are those that will significantly advance a project beyond what would be possible through individual efforts. Contributions to the synergy of this mechanism are expected to be balanced between the two investigators unless otherwise justified. It should be clear that both investigators have an equal level of intellectual input into the proposed project. This award mechanism is designed to support completely new ideas, not ideas that are extensions of existing collaborative efforts. New collaborations are strongly encouraged but not required. If the investigators have a history of collaboration, then they must clearly demonstrate how the proposed research is a new synergistic effort. Examples of a collaboration that is not synergistic and will not be considered for funding under this award mechanism include: • Reagents supplied by one collaborator and molecular studies completed by the other collaborator. • Service function or core support providing laboratory investigations or statistical analyses. • Projects that can be accomplished in a single PI's laboratory. Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16802>

Department of Defense

Dept. of the Army -- USAMRAA

DoD Neurofibromatosis Investigator-Initiated Research Award Modification 2

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-IIRA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 11, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$3,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding. The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over today's approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3)

enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:• Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;• Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;• Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;• Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials. Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:• The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.• If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.• The collaborator must be at or above the level of Assistant Professor (or equivalent).• At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16780>

Department of Defense
Office of Naval Research
Naval Supply Systems Command
National Security Science and Engineering Faculty Fellowship (NSSEFF) Program
Modification 5

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	NPSBAA08-001
Opportunity Category:	Discretionary
Posted Date:	Jan 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Mar 28, 2008
Current Closing Date for Applications:	Mar 28, 2008

Archive Date:	Apr 27, 2008
Funding Instrument Type:	Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	
Estimated Total Program Funding:	
Award Ceiling:	
Award Floor:	
CFDA Number:	12.300 -- Basic and Applied Scientific Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Public and State controlled institutions of higher education
Private institutions of higher education

Description

The Naval Postgraduate School (NPS) will receive applications for the National Security Science and Engineering Faculty Fellowships (NSSEFF) Program. The Department of Defense (DoD), Office of the Director, Defense Research and Engineering (DDR&E) has established the NSSEFF program with the following objectives: provide extensive, long-term financial support to distinguished university faculty scientists and engineers to conduct unclassified, fundamental research on topics of interest to DoD; ensure that our nation has an active, long-term, well informed, and aggressive research and engineering portfolio that attracts creative and energetic scientists, engineers, and their students. The Fellowship is open to U.S. citizens whose earned Ph.D. was awarded within the past 25 years. Accredited, degree-granting educational institutions may nominate distinguished faculty scientists and engineers to receive National Security Science and Engineering Faculty Fellowships. The Fellows will be selected based on competitive evaluations of the scientific and technical merit of the nominees' white papers and proposals. It is anticipated that as many as 10 fellowships will be awarded each fiscal year. Each Fellow will receive up to \$3,000,000 in long-term financial support (up to \$600,000 per year for up to five (5) consecutive years) to conduct fundamental research on topics of interest to DoD. Fellows are expected to produce quantifiable research results over the five-year period of the grant. Fellows are also expected to participate in all NSSEFF activities. Although the intent for the fundamental research is to be unclassified, each Fellow must hold a Secret security clearance. The NSSEFF program will expose Fellows to classified information necessary to inform the objectives, approach, and conduct of their fundamental research. A current Secret security clearance is not required at the time of application. However, Fellows must be granted and maintain a final Secret clearance to receive program funding. Grants will be made to the Fellow's university in accordance with all applicable laws and

regulations, but the award is portable with the individual Fellow. The Fellows will be required to be full and active participants in all NSSEFF activities, provide annual reports of research progress and financial management to the Department, and brief DoD leadership in person at least once each year on their research progress and results. Research topics should be aligned with the Desired Capabilities S&T Investment Areas or the Enabling Technology Investment Areas or from the 2007 Director of Defense Research and Engineering (DDR&E) Strategic Plan. Before selecting research topic(s), a thorough reading the Strategic Plan is highly recommended. Additional details are available at: http://www.dod.mil/ddre/doc/Strategic_Plan_Final.pdf

Link to Full Announcement

[Link to All NPS BAA's](#)

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16422>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Synergistic Idea Award
Modification 2

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded). In addition, this modification corrects the Helpdesk e-mail address in the application package to read cdmrp.pa@amedd.army.mil.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-SIA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	25
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	

Award Floor:

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Synergistic Idea Award mechanism was first offered in FY06. Since that time, 718 Synergistic Idea Award proposals have been received and 58 have been recommended for funding. The Synergistic Idea Award supports collaborations between two independent investigators who address an innovative, high-risk, potentially high-reward breast cancer research question from synergistic and complementary perspectives. The Synergistic Idea Award is designed to promote new ideas and new collaborations. Proposals are not required to include preliminary data, but a rationale for the work must be provided. Proposals should have a high probability of revealing new avenues of investigation. The Synergistic Idea Award requires the submission of a single proposal that addresses a critical issue in breast cancer research. Proposals must clearly identify the synergy that will enable or greatly accelerate the evaluation of a single innovative hypothesis. The BCRP seeks proposals from all areas of laboratory clinical, behavioral, and epidemiological research. Multi-institutional and/or multidisciplinary proposals are encouraged but not required. Collaborators not from distinct disciplines must clearly explain why the proposed research is synergistic. Innovation, synergy, and impact are important aspects of the Synergistic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that is not innovative and will not be considered for funding under this award mechanism include: • Investigating the next logical step or incremental advancement of published data. • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. Synergy: Research combinations demonstrating synergy are those that will significantly advance a project beyond what would be possible through individual efforts. Contributions to the synergy of this mechanism are expected to be balanced between the two investigators unless otherwise justified. It should be clear that both investigators have an equal level of intellectual input into the proposed project. This award mechanism is designed to support completely new ideas, not ideas that are extensions of existing collaborative efforts. New collaborations are strongly encouraged but not required. If the investigators have a history of collaboration, then they must clearly demonstrate how the proposed research is a new synergistic effort. Examples of a collaboration that is not synergistic and will not be considered for funding under this award mechanism include: • Reagents supplied by one

collaborator and molecular studies completed by the other collaborator. • Service function or core support providing laboratory investigations or statistical analyses. • Projects that can be accomplished in a single PI's laboratory. Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16802>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Translational Research Partnership Modification 2

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile (Expanded).

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-TRP
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$2,500,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Translational Research Partnership Award was first offered in FY07 to support partnerships between clinicians and laboratory scientists to conduct translational research in ovarian cancer. During this time, 22 proposals were received for the Translational Research Partnership Award, and 5 were recommended for funding. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that accelerate the movement of promising ideas in ovarian cancer into clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in ovarian cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a laboratory scientist and the other must be a clinician, and it should be clear that both have had equal intellectual input into the design of the research project. At least one member of the partnership must have experience either in ovarian cancer research or ovarian cancer patient care. Historically Black College and Universities/Minority Institutions are encouraged to apply. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into the clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. Developing the research plan must involve a reciprocal flow of ideas and information within the partnership. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at (<http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals>). These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Translational Research Partnership Award does not support clinical trials, but may support correlative studies that are associated with an existing clinical trial and projects that develop clinical endpoints for clinical trials. Research projects may also include preclinical studies in animal models and human subjects and human anatomical substances. This award is intended to support both new and established scientists across a broad spectrum of disciplines in research projects that are likely to make a major impact on ovarian cancer. NEW FOR FY08 – The Translational Research Partnership award accepts proposals from all areas of research, but encourages research from these Areas of Encouragement:• Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. This award mechanism is not intended to support the study of new combinations of conventional ovarian cancer therapies. The use of

existing resources is encouraged, including libraries of compounds or probes, tissue repositories such as those managed by the Gynecologic Oncology Group, and other existing sets of tissue, blood, or images. Important aspects of the Translational Research Partnership Award are as follows:1. Partnership: The success of the project depends on the unique skills and contributions of each partner. • Optional Non-traditional Partnership (NEW FOR FY08): This award encourages a partnership between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional partnership is to leverage resources in the ovarian cancer research community. It is expected that in addition to providing intellectual input, the optional non-traditional partnership will contribute research resources (e.g., supplies, reagents, equipment, personnel) and/or financial resources.2. Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas in ovarian cancer into clinical applications.3. Preliminary Data: Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in ovarian cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16815>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Prostate Cancer Synergistic Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-SIDA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$5,600,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research

and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Synergistic Idea Development Award mechanism was introduced in FY07. Since then, a total of 73 proposals have been received and 8 (representing 18 individual awards) have been recommended for funding. The Synergistic Idea Development Award supports innovative, high-risk/high-gain approaches to prostate cancer research involving two or three independent, faculty-level (or equivalent) PIs. These investigators should use synergistic and complementary perspectives to address a central problem or question in prostate cancer research. This award is designed to encourage and support both new and pre-existing partnerships. The overall goal of this award is to accelerate advances in prostate cancer research to support the PCRP vision of conquering prostate cancer. The Synergistic Idea Development Award requires that investigators jointly design a single project. However, each partner will be recognized as a PI, submit a separate proposal, and receive an individual award. The proposal must be supported by the unique expertise of each PI, and must clearly define the synergistic components that will facilitate and accelerate progress in a way that could not be accomplished through independent efforts. Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include clearly stated plans for interactions among all PIs and institutions involved. The plans must include ongoing communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional proposals must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. NEW FOR FY08: Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16878>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Clinical Trial Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-CTA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$2,700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Clinical Trial Award mechanism was introduced in FY01. Since then, 71 proposals have been received and 16 have been recommended for funding. The Clinical Trial Award supports rapid execution of Phase 0/I, Phase I, Phase I/II, or Phase II clinical trials with the potential to have a significant impact on prostate cancer prevention, detection, diagnosis, or treatment. Studies in a broad range of areas related to prostate cancer clinical management and care will be accepted under this mechanism, including but not limited to: • Evaluations of novel drugs, biologics, or devices • Survivorship • Diet • Quality of life • Psychosocial interventions • Behavioral studies Exploratory clinical trials (Phase 0) may be submitted, but they must be accompanied by a Phase I clinical trial (Phase 0/I). PIs must clearly specify in their proposals which type of clinical trial, Phase 0/I, Phase I, Phase I/II, or Phase II, is being proposed. Please refer to <http://www.clinicaltrials.gov/> for definitions and descriptions of each type of clinical trial. Each proposal must include only one clinical trial. PIs are encouraged to pursue correlative studies that accompany their trials. PIs conducting correlative studies must describe in detail the study aims, procedures or methods, and plans for data management and analysis, including an

appropriately powered statistical plan. It is expected that the intervention, drug, or device to be used in the proposed trial will be available in sufficient quantities and ready for clinical trials at the time that the award is made. Further, it is expected that the clinical trial will be initiated within 12 months of the award date. Note that Investigational New Drug (IND)/Investigational Device Exemption (IDE) approvals, if applicable, should be in process or completed before submission of an application to this mechanism. If IND/IDE approval is not received by April 30, 2009, the Government reserves the right to not fund the award. Funding from this award mechanism cannot be used for preclinical research studies.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16879>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Laboratory-Clinical Transition Award: Stage I Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-LCTAI
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$5,400,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

1. Overview The PCRP Laboratory-Clinical Transition Award: Stage I mechanism was introduced in FY07. Since then, 17 proposals have been received and 3 have been recommended for funding. The Laboratory-Clinical Transition Award: Stage I represents the first step of a three-step sequence to foster the bench-to-bedside transition of promising agents into the clinic to benefit prostate cancer patients. The Laboratory-Clinical Transition Award: Stage I supports goal- and product-driven preclinical studies of lead agents that have the potential to revolutionize the prevention, detection, or treatment of prostate cancer. The second step, the Laboratory-Clinical Transition Award: Stage II, will fund production and testing of current Good Manufacturing Practices (cGMP) agents before clinical trials. The Laboratory-Clinical Transition Award: Stage II, described briefly at the end of this section, will be offered in FY10 pending availability of funds. The third step, conduct of Phase I and Phase II clinical trials of the cGMP-produced agent, may be sponsored through the PCRP Clinical Trial Award, which is anticipated to be offered yearly pending availability of funds, or similar award mechanisms from other funding sources.

2. Laboratory-Clinical Transition Award: Stage I The Laboratory-Clinical Transition Award: Stage I is intended to fund PIs who lack support to conduct the preclinical studies needed to advance lead agents to human testing. The goal of this award is the generation of sufficient data to justify inclusion of lead agents into future clinical trials for the prevention, detection, or treatment of prostate cancer. For the purposes of the Laboratory-Clinical Transition Award: Stage I, lead agents are defined as biological or chemical therapeutics, imaging agents, or preventive agents that have potential clinical application to prostate cancer. Examples of lead agents include but are not limited to: novel chemotherapeutics, antibodies, viral particles, and contrast agents. PIs are expected to identify and have access to either one lead agent or a limited number of lead agents for optimization at the time of proposal submission. All Laboratory-Clinical Transition Award: Stage I proposals must include preliminary data relevant to the lead agent(s) under development. Preliminary data must provide information regarding target availability and distribution in human prostate cancer tissues and must support the relevance of the target for the prevention, detection, or treatment of human prostate cancer. Preliminary data must also support the efficacy of each agent in model systems. The National Cancer Institute has constructed developmental pathways for translational research (http://www.cancer.gov/images/trwg/Developmental-Pathway-Agent-Drug_Biologics.pdf) that may be useful for designing translational research studies for support under this mechanism. These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Laboratory-Clinical Transition Award: Stage I only supports research from the identification of a lead agent up to but not including cGMP production of the agent. This award may not be used to conduct clinical trials. Studies that may be funded under this award include, but are not limited to:

- Comparative activity/efficacy testing to define a single lead agent from a limited library of candidates. Such studies must be completed within 12 months of the start date of the award. If the studies are not completed within 12 months of award initiation, funding for the award may be terminated.
- Toxicology screening
- Drug metabolism, biodistribution, and pharmacokinetic assays
- Pharmacodynamic studies
- Radiation dosimetry
- Development and

validation of assays and reagents required to measure biological responses and molecular endpoints. Studies that may NOT be funded under this award include, but are not limited to:

- Target discovery
- Drug screening
- Development of devices
- Development of serum- or tissue-based biomarkers for the primary diagnosis of disease
- New combinations or formulations of conventional therapeutics

Preclinical studies involving human subjects or specimens will be supported only if they are exempt under Title 32 of the Code of Federal Regulations Section 219.101(b)(4) (32 CFR 219.101(b)(4)) or qualify for expedited review under 32 CFR 219.110 or 21 CFR 56.1102. Studies that do not qualify for exempt status or expedited review will be administratively withdrawn and will not be funded. The preclinical drug development process may require resources beyond those available at a single laboratory or institution. As such, the PI must disclose any patents, issued or pending, and/or licenses, granted and/or pending, with respect to the lead agent(s) as well as any known patents that block the development of the lead agent(s). In the event that the project requires the use of a non-commercially available technology/material that is patented by a third party, the PI must provide documentation that the third party patent holder does not object to the PI's use of the patented technology/material. Since the ultimate goal of translational research is to obtain Investigational New Drug (IND) approvals on lead agents, PIs are expected to abide by US Food and Drug Administration (FDA) proposed and existing regulations governing the conduct of preliminary studies and the collection of data in support of an IND application (refer to http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm). Please note that the focus of the Laboratory-Clinical Transition Award: Stage I is to support the optimization of an identified lead agent up to but not including cGMP production of the agent. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism.

3. Laboratory-Clinical Transition Award: Stage II

The Laboratory-Clinical Transition Award: Stage II will facilitate and expedite the next stage of the bench-to-bedside transition of promising lead agents by funding:

- Full-scale cGMP production of the agent for clinical trials.
- Studies with the cGMP-produced agent (e.g., toxicology and pharmacology) to support an IND application (or equivalent) to the FDA or other regulatory agency.
- Development of a clinical protocol for submission to the PCRP Clinical Trial Award or a clinical trial award mechanism from another funding source.

Collaboration with the existing PCRP Clinical Consortium for protocol development will be encouraged but not required. All PIs funded by the Laboratory-Clinical Transition Award: Stage I who have viable lead agents are encouraged to compete for the Laboratory-Clinical Transition Award: Stage II, which is anticipated to be offered in FY10 pending receipt of appropriations. The Laboratory-Clinical Transition Award: Stage II will also be open to PIs who have not submitted to or been funded by the Laboratory-Clinical Transition Award: Stage I. Full guidance regarding the format and content of the Laboratory-Clinical Transition Award: Stage II proposal will be provided in the Program Announcement for the Laboratory-Clinical Transition Award: Stage II. Please note that there is no guarantee that funds will be available for the Laboratory-Clinical Transition Award: Stage II.

Link to Full Announcement

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Clinical Consortium Award Grant Modification 3

Description of Modification

The purpose of this modification is to clarify the performance period for the Coordinating Center. The Coordinating Center performance period is 5-years. See the revised Program Announcement for this clarification.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-CCA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 20, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	13
Estimated Total Program Funding:	\$25,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted

Description

General Information: The PCRP Clinical Consortium Award mechanism was introduced in FY05. Since then, 19 proposals have been received and 11 have been recommended for funding. Of these, 2 proposals were for the Coordinating Center, with one being funded, and 17 were for Clinical Research Sites, with 10 being funded. The Clinical Consortium Award does not provide funding for

research, but, rather, provides the support to develop the collaborations and resources necessary for the consortium to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) clinical trials of therapeutic agents or approaches for the management or treatment of prostate cancer. Trials that incorporate clinical validation of novel biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are strongly encouraged. The overarching goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market novel therapeutic interventions that will ultimately decrease the overall impact of the disease. PIs from both US and international institutions may apply. Submissions from institutions with enhanced access to patients from disproportionately affected populations are encouraged. It is expected that the consortium will achieve financial self-sufficiency during the award period such that consortium activities can continue after funding through this mechanism ends. The consortium will consist of approximately 12 Clinical Research Sites and one Coordinating Center. These participants will be jointly responsible for proposing, selecting, and conducting Phase II and Phase I/II clinical trials focused on prostate cancer therapeutic interventions. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16882>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Health Disparity Research Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-HDRA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	8
Estimated Total Program Funding:	\$3,200,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Health Disparity Research Award mechanism was introduced in FY01. Since then, 95 proposals have been received and 30 have been recommended for funding. The Health Disparity Research Award reflects the PCRP's commitment to resolving disparities in prostate cancer incidence, morbidity, and mortality by funding health disparity-focused projects by investigators at multiple points in their careers:

- Transitioning Investigators: Mentored investigators transitioning into their first independent faculty position and establishing their own independent research programs.
- Early-Career Investigators: Independent investigators in the early stages of their careers.
- Established Investigators: Independent investigators at or above the Assistant Professor level or equivalent.

Appropriate disparity focus areas include, but are not limited to:

- Race and ethnicity,
- Socioeconomic status,
- Access to health care,
- Insurance status,
- Age,
- Geography, and
- Cultural beliefs.

PIs who do not have either experience in prostate cancer research or a connection to, or effectiveness in working with, an affected population or community are strongly encouraged to include a collaborator (or collaborators) with the appropriate prostate cancer or health disparity research experience. Such experience may include:

- Being a member of the affected population or community with a demonstrated commitment to the affected population or community;
- Having experience working with the affected population or community; or
- Having interactions with or an active membership in organizations such as the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, Patient Advocate Foundation National African American Outreach Program, or Prostate Health Education Network (PHEN).

In addition, the proposal must explicitly state how the proposed research is related to a health disparity focus area in prostate cancer. This award may support research with laboratory animals and human biological substances, as well as research with human subjects that does not involve clinical trials. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16883>

DOD Prostate Cancer Health Disparity Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-HDTA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	6
Estimated Total Program Funding:	\$700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Health Disparity Training Award was introduced in FY01. Since then, 24 proposals have been received and 12 have been recommended for funding. The Health Disparity Training Award supports training opportunities focused on prostate cancer disparity for individuals in the early stages of their careers. The award funds research under the guidance of a mentor who is an experienced prostate cancer health disparity researcher. PIs may apply for predoctoral and postdoctoral traineeships through this award mechanism. Appropriate disparity focus areas can include, but are not limited to: • Race and ethnicity, • Socioeconomic status, • Access to health care, • Insurance status, • Age, • Geography, and • Cultural beliefs. The mentor must demonstrate a connection to, or effectiveness in working with, the affected population or community. Such connection(s) may include: • Being a member of the affected population or community with a demonstrated commitment to the affected population or community; • Having experience working with the affected population or community; or • Having interactions with and/or active membership in

organizations such as the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, Patient Advocate Foundation National African American Outreach Program, or Prostate Health Education Network (PHEN). The proposal must explicitly state how the proposed research is related to a health disparity focus area in prostate cancer. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer health disparity researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer health disparity research. All Health Disparity Training Award proposals are to be written with appropriate direction from the mentor and signed by the trainee as the PI and author of the proposal. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16884>

Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Career Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-CAR
Opportunity Category:	Discretionary
Posted Date:	Feb 25, 2008
Creation Date:	Feb 25, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	6
Estimated Total Program Funding:	\$3,300,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Career Development Award (NEW FOR FY08) is intended to support research training opportunities for investigators wishing to pursue an independent career in ovarian cancer research. This award supports individuals in the early stages of their careers by providing the opportunity to obtain the funding and experience necessary to pursue an independent career at the forefront of ovarian cancer research. Key elements of this award include:

- **Principal Investigator:** PIs may be research- or physician-scientists at either the postdoctoral or early-career level. Investigators from Historically Black Colleges and Universities/Minority Institutions are encouraged to apply.
- **Ovarian Cancer Mentorship:** A designated mentor is required. This mentor must be an established ovarian cancer researcher; have ovarian cancer funding (past and present); and have a record of ovarian cancer publications in peer reviewed journals. In addition, the mentor must demonstrate a commitment to developing and sustaining the PI's independent research career in ovarian cancer research.
- **Career Development:** The Career Development Plan should be prepared with guidance from the mentor. The proposal should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of ovarian cancer research. The plan should outline how the PI will be trained in ovarian cancer research. Because career development is the focus of this award, the institution must demonstrate a commitment to the PI through protected time: at least 50% for a research Postdoctoral Fellow PI and at least 25% for the Physician-Scientist PI or Early-Career PI.
- **Research Strategy:** Studies in all areas of ovarian cancer-focused research may be proposed for the Career Development Award; however, research from one of the three areas listed below is encouraged (NEW FOR FY08):
 - o Identification and characterization of early changes associated with ovarian cancer.
 - o Identification and characterization of ovarian cancer stem cells.
 - o The contribution of the stroma to the tumor microenvironment in ovarian cancer.Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. Clinical trials are not allowed under this award mechanism. The Career Development Award is a Phase I Award. All PIs funded by this award will be encouraged to compete for an independent Phase II award designed to sustain independent ovarian cancer researchers. It is anticipated that the Phase II award will be offered in FY11, pending availability of Federal funds for this program.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16943>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Neurofibromatosis Clinical Trial Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-CTA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$1,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Clinical Trial Award (CTA) mechanism was created in FY99. Since then, 18 Clinical Trial Award proposals have been received, and 3 have been recommended for funding. The NFRP Clinical Trial Award supports clinical research with the potential to have a major impact on the treatment and/or management of neurofibromatosis and/or Schwannomatosis. Funding from this award mechanism cannot be used for preclinical research studies. Clinical Trial Awards will support Phase 0, Phase I, and Phase II clinical trials (please refer to <http://www.clinicaltrials.gov> and www.fda.gov/cder/guidance/6384dft.htm for descriptions of each type of clinical trial). Applicants must clearly specify in their proposals which type of clinical trial is being proposed: Phase 0, Phase I, or Phase II. Each proposal should contain only one clinical trial with a distinct study design. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is

required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. If the trial is multi-institutional, applicants should include plans for communication and real-time data transfer between the collaborating institutions as well as how specimens and/or imaging products obtained during the study will be handled in the appropriate sections of the Clinical Protocol. An intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials as part of the Supporting Documentation. Important aspects of the Clinical Trial Award are as follows: • The proposal must include a named study coordinator who will guide the clinical protocol through Institutional Review Board (IRB), Human Subjects Research Review Board (HSRRB), and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. • IRB approvals should be in process or completed before submission of the proposal to the Clinical Trial Award mechanism. • The results of the clinical trial should have a clear and important impact. • The clinical trial must have clearly defined and appropriate endpoints. • The PI must demonstrate availability of and access to an appropriate patient population that will support a meaningful outcome for the study.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16779>

Department of Defense

Dept. of the Army -- USAMRAA

DoD Neurofibromatosis Investigator-Initiated Research Award Grant

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-IIRA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 11, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$3,000,000
Award Ceiling:	
Award Floor:	

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding. The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over today's approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3) enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:

- Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;
- Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;
- Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
- Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:

- The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.
- If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.
- The collaborator must be at or above the level of Assistant Professor (or equivalent).

At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16780>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Neurofibromatosis New Investigator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-NIA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$1,350,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP New Investigator Award mechanism (NIA) was created in FY99. Since then, 150 New Investigator Award proposals have been received, and 34 have been recommended for funding. The intent of the NFRP New Investigator Award is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Eligible Principal Investigators (PIs) must be at or below the level of Assistant Professor (or equivalent), must have received no more than \$300K in direct costs for NF research as a PI of a federally funded, non-mentored peer reviewed grant, and must have not received a NIA from any CDMRP program previously.

Experience in NF research is allowed, but not required. However, PIs with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. NIA proposals must include preliminary data relevant to NF and the proposed project. The FY08 NFRP encourages proposals that specifically address critical needs of the NF Community in the following areas: • Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; • Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; • Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; • Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials. Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborator and address the following requirements: • The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without their involvement. • If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history. • The collaborator must be at or above the level of Assistant Professor (or equivalent). • At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16781>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Neurofibromatosis Exploration – Hypothesis Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-EHDA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008

Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$350,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Exploration – Hypothesis Development Award (EHDA) mechanism is being offered for the first time in FY08. The NFRP Exploration – Hypothesis Development Award supports the initial exploration of innovative, untested, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or it should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. Some gaps in supporting rationale may exist due to a lack of available information. The presentation of preliminary data is encouraged, but not required. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b). Studies that do not qualify for exempt or expedited status during review at any level will be administratively withdrawn and will not be funded. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas: • Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; • Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; • Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; • Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Link to Full Announcement

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-IDA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	55
Estimated Total Program Funding:	\$31,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Idea Development Award mechanism was introduced in FY97. Since then, 4,330 proposals have been received and 831 have been recommended for funding. The Idea Development Award supports innovative, high-risk/high-gain approaches to prostate cancer research. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. NEW FOR FY08: Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Important aspects of the Idea Development Award are as follows: 1. Innovation: Innovative research may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the

responsibility of the PI to clearly and explicitly articulate how the proposed research is innovative. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this mechanism. 2. Impact: Research that has high impact will, if successful, significantly advance current methods and concepts for the prevention, detection, diagnosis, or treatment of human prostate cancer. It is the responsibility of the PI to clearly and explicitly articulate the potential impact the proposed research will have on human prostate cancer. 3. Preliminary Data: NEW FOR FY08: Submission of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Although groundbreaking research often involves a degree of risk due to unforeseen difficulties or results, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16804>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer New Investigator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-NIA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	23
Estimated Total Program Funding:	\$7,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP New Investigator Award mechanism was introduced in FY99. Since then, 1,678 proposals have been received and 365 have been recommended for funding. The New Investigator Award supports independent PIs in the early stages of their careers. The PCRP seeks PIs who have innovative, high-impact ideas or new technologies applicable to prostate cancer research, prevention, detection, diagnosis, or treatment. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Important aspects of the New Investigator Award are as follows: 1. Personnel: The PI and collaborator are emphasized in this award. The PI's record of accomplishment will be evaluated regarding his or her potential for contributing to the prostate cancer research field. The PI and collaborator together will be emphasized in peer review to determine whether their combined background and prostate cancer-related expertise demonstrate the ability to accomplish the proposed work. 2. Innovation: Innovative research may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the responsibility of the PI to clearly and explicitly articulate how the proposed research is innovative. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this mechanism. 3. Impact: Research that has high impact will, if successful, significantly advance current methods and concepts for the prevention, detection, diagnosis, or treatment of human prostate cancer. It is the responsibility of the PI to clearly and explicitly articulate the potential impact the proposed research will have on human prostate cancer. 4. Collaborator: Submission to this award mechanism requires a collaborator (or collaborators), appropriate to the proposal, who has experience in prostate cancer research, as demonstrated by a record of funding and publications in prostate cancer research. 5. Preliminary Data: To encourage submissions from PIs early in their careers, proposals are not required to have preliminary data. Although groundbreaking research often involves a degree of risk due to unforeseen difficulties or results, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16805>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Physician Research Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-PRTA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	8
Estimated Total Program Funding:	\$4,700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Physician Research Training Award was introduced in FY03. Since then, 82 proposals have been received and 32 have been recommended for funding. The Physician Research Training Award supports a mentored training experience to prepare physicians with clinical duties and/or responsibilities for a productive career in prostate cancer research. The PI must be in the last year of an accredited medical residency or medical fellowship program, or within the first 3 years following his or her appointment as an Instructor, Assistant Professor, or equivalent. A training program appropriate to the area of study, which may include coursework and seminars, that will provide the PI with experience in key areas such as statistics, bioethics, and/or relevant basic science disciplines, must be part of the application. This award requires the involvement of a designated mentor with an established research program in prostate cancer. Funds from this award are intended to provide aggressive protection, at least 40%, of the PI's time for research. The PI must demonstrate a commitment to a career in prostate cancer research and clinical practice. In addition, up to 50% of a key support person's salary may be provided by this award. Up to \$10,000 in funds per year from this award may be used for research supplies, equipment, and travel to

scientific/technical meetings. These funds may be used for research with laboratory animals and human biological substances, as well as research with human subjects that does not involve clinical trials. PIs may participate in clinical trials as part of their training for this award, but funding for the clinical trials must come from a source other than this award. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16807>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Innovator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-INNOV
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$6,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Innovator Award was first offered in FY01. Since that time, 176 Innovator Award proposals have been received and 16 have been recommended for funding. The Innovator Award supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to, breast cancer. These individuals will have the most potential for future ground breaking achievements in breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could ultimately lead to the eradication of breast cancer. Individuals may be from diverse organizations including, but not limited to, academic institutions, advocacy groups, government agencies, the private sector, the media, and/or professional societies. Since the intent of the Innovator Award mechanism is to recognize creative and innovative individuals rather than projects, the central feature of the award is the innovative contribution that the recipient can make to the eradication of breast cancer. As such, an individual selected to submit a full proposal is required to submit an essay addressing his or her area(s) of focus and how he or she will use the award to pursue his or her most creative vision in breast cancer research. The primary criteria for making these awards will be an individual's past record of creativity, their promise for continued innovation in future work, and an indication of how this award will create and further innovative strategies to solve the breast cancer problem. Experience in breast cancer research is not required; however, the proposal must focus on breast cancer and it is expected that the recipient will commit a minimum of 50% of his or her full-time professional effort to breast cancer research during the tenure of this award.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16808>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-PCTA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	

Expected Number of Awards: 31
Estimated Total Program Funding: \$3,400,000
Award Ceiling:
Award Floor:
CFDA Number: 12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Prostate Cancer Training Award was introduced in FY06. Since then, 271 proposals have been received and 118 have been recommended for funding. The Prostate Cancer Training Award supports training opportunities focused on prostate cancer research or patient care for individuals in the early stages of their careers. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer research. All Prostate Cancer Training Award proposals are to be written with appropriate direction from the mentor and signed by the trainee as the PI and author of the proposal. PIs may apply for predoctoral and postdoctoral traineeships through this award mechanism.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16809>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Impact Award Grant

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-08-BCRP-IMPT
Opportunity Category: Discretionary
Posted Date: Feb 07, 2008
Creation Date: Feb 07, 2008
Original Closing Date for Applications: May 07, 2008
Current Closing Date for Applications: May 07, 2008

Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Impact Award mechanism was first offered in FY07. Since that time, 86 Impact Awards proposals have been received and none have been recommended for funding. The Impact Award supports unique projects or ideas (from small- to large-scale) that possess strong potential to have an unprecedented impact in breast cancer. The most important aspect of this mechanism is the potential of the proposed work to have an extraordinarily high impact and contribute significantly to the goal of eradicating breast cancer. The potential impact may be scientific or clinical and may be near-term or long-term. The proposed work may be from any discipline or combination of disciplines and must be based on a solid overall research strategy. The BCRP seeks proposals from all areas of basic, translational, clinical, behavioral, and epidemiological research. The Impact Award mechanism particularly encourages proposals from underdeveloped and/or underexplored topic areas. Proposals are expected to present ideas that are above and beyond those that fit current award mechanisms offered by the BCRP.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16811>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-IDA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$2,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Idea Development Award mechanism was offered in FY02 through FY06 to support innovative research in ovarian cancer. During this time, 616 proposals have been received and 51 OCRP Idea Development Awards have been made. The OCRP Idea Development Award supports high impact, innovative research that will drive the field forward. NEW FOR FY08 – This award seeks proposals from all areas of ovarian cancer research. However, for FY08, this award encourages proposals that address critical needs of the ovarian cancer community in the following areas: • Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. Important aspects of the Idea Development Award are as follows: 1. Impact: The proposed research should have a significant impact on the concepts or methods that drive the field of ovarian cancer research. The proposed research is expected to make original and important contributions to the goal of advancing ovarian cancer research and/or ovarian cancer patient care. 2. Innovation:

Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. Examples of research that are not innovative and that will not be considered for funding under this mechanism include: Exploring a previously tested hypothesis in a different cell line; using a published series of in vitro assays to further characterize a model system; and incorporating known biomarkers into in vitro or clinical models of ovarian cancer. 3. Preliminary Data: Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. 4. Proposals Involving Clinical Trials: If a proposal requests support for a clinical trial, the PI is required to submit a clinical protocol in addition to the proposal by the proposal receipt deadline. Such trials must have a clinical coordinator who has sufficient time dedicated to the project to carry out the record keeping, coordination, and/or other administrative duties the project entails. The protocol will be reviewed separately. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. 5. Optional Non-traditional Collaboration (NEW FOR FY08): The FY08 OCRP Idea Development Award strongly supports collaborative research between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional collaboration is to increase the leveraging of resources in the ovarian cancer research community. The collaborator in this optional non-traditional collaboration must contribute at least 10% level of effort to the project (as reflected in the budget) and provide intellectual input and research resources (e.g., supplies, reagents, equipment, personnel), or intellectual input and financial resources. Collaborations that bring new perspectives from other disciplines or bring new investigators into the ovarian cancer field are also strongly encouraged. Consequently, if the PI does not have experience in ovarian cancer, then the collaborator must have ovarian cancer experience, as demonstrated through publications in the field, funding history, and/or patient care.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16813>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Translational Research Partnership Grant

This Program Announcement is modified to incorporate a new revised application package.
PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION

PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded).

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-TRP
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$2,500,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Translational Research Partnership Award was first offered in FY07 to support partnerships between clinicians and laboratory scientists to conduct translational research in ovarian cancer. During this time, 22 proposals were received for the Translational Research Partnership Award, and 5 were recommended for funding. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that accelerate the movement of promising ideas in ovarian cancer into clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in ovarian cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a laboratory scientist and the other must be a clinician, and

it should be clear that both have had equal intellectual input into the design of the research project. At least one member of the partnership must have experience either in ovarian cancer research or ovarian cancer patient care. Historically Black College and Universities/Minority Institutions are encouraged to apply. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into the clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. Developing the research plan must involve a reciprocal flow of ideas and information within the partnership. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at (<http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals>). These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Translational Research Partnership Award does not support clinical trials, but may support correlative studies that are associated with an existing clinical trial and projects that develop clinical endpoints for clinical trials. Research projects may also include preclinical studies in animal models and human subjects and human anatomical substances. This award is intended to support both new and established scientists across a broad spectrum of disciplines in research projects that are likely to make a major impact on ovarian cancer. NEW FOR FY08 – The Translational Research Partnership award accepts proposals from all areas of research, but encourages research from these Areas of Encouragement: • Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. This award mechanism is not intended to support the study of new combinations of conventional ovarian cancer therapies. The use of existing resources is encouraged, including libraries of compounds or probes, tissue repositories such as those managed by the Gynecologic Oncology Group, and other existing sets of tissue, blood, or images. Important aspects of the Translational Research Partnership Award are as follows: 1. Partnership: The success of the project depends on the unique skills and contributions of each partner. • Optional Non-traditional Partnership (NEW FOR FY08): This award encourages a partnership between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional partnership is to leverage resources in the ovarian cancer research community. It is expected that in addition to providing intellectual input, the optional non-traditional partnership will contribute research resources (e.g., supplies, reagents, equipment, personnel) and/or financial resources. 2. Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas in ovarian cancer into clinical applications. 3. Preliminary Data: Preliminary data to support

the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in ovarian cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16815>

Department of Defense
Air Force Office of Scientific Research
Research Interests of the Air Force Office of Scientific Research Modification 3

Description of Modification

This BAA has been superseded by AFOSR-BAA-2008-1.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	AFOSR-BAA-2007-1
Opportunity Category:	Discretionary
Posted Date:	Sep 30, 2006
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	This announcement is AFOSR BAA 2007-1 and supersedes AFOSR BAA 2006-1. This announcement is open-ended until revised and should be referenced on all responses.
Current Closing Date for Applications:	This announcement is AFOSR BAA 2007-1 and supersedes AFOSR BAA 2006-1. This announcement is open-ended until revised and should be referenced on all responses.
Archive Date:	Feb 07, 2008
Funding Instrument Type:	Cooperative Agreement Grant Procurement Contract
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	
Estimated Total Program Funding:	
Award Ceiling:	
Award Floor:	
CFDA Number:	12.800 -- Air Force Defense Research Sciences Program
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Additional Information on Eligibility:

All responsible, potential applicants from academia and industry are eligible to submit proposals. AFOSR particularly encourages proposals from small businesses, historically black colleges and universities, minority institutions and minority researchers. However, no portion of this BAA is set aside for a specific group.

Description

AFOSR plans, coordinates, and executes the Air Force Research Laboratory's (AFRL) basic research program in response to technical guidance from AFRL and requirements of the Air Force; fosters, supports, and conducts research within Air Force, university, and industry laboratories; and ensures transition of research results to support USAF needs. The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in three scientific directorates: Aerospace and Materials Sciences, Physics and Electronics, and Mathematics, Information and Life Sciences. If the Full Announcement Link is not available on this synopsis, the FULL ANNOUNCEMENT is available on the Grants.gov website by scrolling to the top of the synopsis page and clicking on the "FULL ANNOUNCEMENT" box surrounded by the dotted line.

Link to Full Announcement

[FULL ANNOUNCEMENT AFOSR-BAA-2007-1
http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opld=11104](http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opld=11104)

Department of Defense
Office of Naval Research
Naval Research Laboratory
NRL Wide Broad Agency Announcement BAA-07-01
Modification 4

Description of Modification

This opportunity is modified by revising topic BAA 57-07-03, Shipboard Electronic Warfare. The Surface Electronic Warfare Systems Branch (SEWS) is interested in design concepts that will incorporate advanced technology in the development and demonstration of a prototype Electronic Warfare (EW) system for shipboard application. NRL is looking to fund multiple proposals beginning FY09 under this BAA for prototype EW systems and or subsystems. An industry day to provide additional classified information will be held at NRL on 5 March 2008. Attendance will be limited to three representatives per company. NRL will request proposals based on white papers submitted in response to this BAA and received by 10 April 2008.

Names of persons attending and their security clearance need to be submitted to NRL by 27 February 2008. The POC for submitting visit requests and clearances is Ms. Helen Crosby, voice: 202-767-5931, fax: 202-404-7690, email: Helen.crosby@nrl.navy.mil. The revised topic as well as the complete BAA including proposal preparation instructions, technical points of contact for each topic, and evaluation criteria is available at <http://heron.nrl.navy.mil/contracts/0708baa/baa.htm>

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	NRLBAA-07-01
Opportunity Category:	Discretionary
Posted Date:	May 11, 2007
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Dec 31, 2008
Current Closing Date for Applications:	Dec 31, 2008
Archive Date:	Dec 31, 2009
Funding Instrument Type:	Grant
Category of Funding Activity:	Science and Technology and other Research and Development
CFDA Number:	12.300 -- Basic and Applied Scientific Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Others

Link to Full Announcement

[NRL Wide Broad Agency Announcement BAA-07-01](http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=13884)
<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=13884>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Era of Hope Scholar Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-EOHS
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant

Category of Funding Activity:	Cooperative Agreement Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Era of Hope Scholar Award mechanism was first offered in FY04. Since that time, 112 Era of Hope Scholar Award proposals have been received and 23 have been recommended for funding. The Era of Hope Scholar Award supports individuals who have high potential for innovation in breast cancer research early in their careers. Nominees for this award should be exceptionally talented, early-career scientists who have demonstrated that they are the "best and brightest" in their field(s) through extraordinary creativity, vision, and productivity. They also should exhibit strong potential for leadership in the breast cancer research community and be able to articulate a vision for the eradication of breast cancer. Individuals should challenge current dogma and demonstrate an ability to look beyond tradition and convention. The Era of Hope Scholar Award proposal must focus on the PI's record of creative and original accomplishments, potential for leadership in the breast cancer research community, and vision for eradicating breast cancer. These aspects of the proposal will receive greater emphasis in the review process than the proposed research project, although the proposed research project also will be considered. Experience in breast cancer research is not required; however, the proposal must focus on breast cancer research and the PI must commit at least 50% of his or her full-time professional effort during the award period to breast cancer research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16794>

DOD Breast Cancer Era of Hope Postdoctoral Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-EHPA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	14
Estimated Total Program Funding:	\$5,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Era of Hope Postdoctoral Award mechanism was first offered in FY06. Since that time, 44 Era of Hope Postdoctoral Award proposals have been received and 16 have been recommended for funding. The Era of Hope Postdoctoral Award supports exceptionally talented recent doctoral graduates who possess both the ambition and the ability to pursue highly innovative breast cancer research during their postdoctoral training. Research proposed for funding by the Era of Hope Postdoctoral Award mechanism should challenge current scientific dogma and demonstrate that the applicant has an ability to look beyond tradition and convention. Award recipients will be expected to challenge the status quo through creative, high-risk, potentially high-gain research that ultimately may lead to the eradication of breast cancer. Candidates for this award should exhibit a strong desire to pursue a career in breast cancer research. Candidates should provide evidence that they are the "best and brightest" among their peers. Proposals must provide evidence of the candidate's potential for success in pursuing innovative research based on his or her qualifications,

characteristics, achievements, and letters of recommendation. Under this award mechanism, the postdoctoral trainee is considered the Principal Investigator (PI) and, as such, should write the project narrative with appropriate direction from the mentor. While the PI is not required to have previous experience in breast cancer research, this research proposal must focus on breast cancer research. The mentor must possess the appropriate expertise in breast cancer, have current peer reviewed breast cancer funding, and clearly demonstrate a commitment to guiding the PI's research and training. The proposed research must be clearly outlined and the innovative nature of the planned research project and/or training must be explicitly stated. Proposals with a multidisciplinary research approach to breast cancer are highly encouraged but not required. The proposal should include information about the mentor's experience in conducting innovative research and how he or she intends to support the PI's innovative breast cancer research endeavors. Proposals involving clinical trials do not meet the intent of this award mechanism. Proposals must provide details on the suitability of the PI's overall training plan for attaining the goals of this mechanism. In addition, proposals must elaborate on the training environment in which the candidate will work and how it will facilitate the candidate's career development as an innovator at the forefront of breast cancer research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16795>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Breast Cancer Clinical Translational Research Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-CTR
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$75,000,000
Award Ceiling:	
Award Floor:	

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Clinical Translational Research (CTR) Award mechanism was first introduced in FY97. Since that time, 216 Clinical Translational Research Award proposals have been received and 40 have been recommended for funding. The CTR Award is intended to promote substantial improvements over current approaches to breast cancer chemoprevention and therapy, including predictive biomarker studies that would better align treatment options with more specific breast cancer subtypes and/or may identify a new way to treat breast cancer patients. These awards are intended to support research projects that are likely to have a major impact on breast cancer by applying promising research findings to the treatment of patients with, or populations at risk for, breast cancer. Principal Investigators (PIs) may have originated projects in their laboratories that will form the basis for translational research leading to clinical trials to be conducted during this award period. Alternatively, PIs may leverage partnerships with industry (if the ability to conduct the required translational research and early phase clinical trial can be demonstrated). Proposals must include preliminary data and a solid rationale to support the feasibility of innovative translational research leading to a prospective clinical trial or study during the course of the award. Proposals also must include a clear experimental plan and a properly powered statistical plan to perform a prospective clinical trial. Investigators must demonstrate availability of and access to an appropriate patient population that will support a meaningful outcome for the study. Proposals addressing predictive biomarker studies must be supported by a previous, retrospective study and must include data validating the methods for the collection, storage, annotation, and analysis of human biological substances.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16799>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Idea Award Grant

Document Type:

Grants Notice

Funding Opportunity Number:	W81XWH-08-BCRP-IDEA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	60
Estimated Total Program Funding:	\$35,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Idea Award mechanism was first offered in FY93. Since that time, 12,797 Idea Award proposals have been received and 1,809 have been recommended for funding. The Idea Award supports highly innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer. The BCRP seeks proposals from all areas of basic, translational, clinical, behavioral, and epidemiological research. The Idea Award is designed to promote new ideas; therefore, proposals need not include preliminary data. Innovation and Impact are the most important aspects of the Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that are not innovative, and will not be considered for funding under this mechanism include: • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. • Investigating the next logical step or incremental advancement of published data.

Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16800>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Synergistic Idea Award Grant

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded). In addition, this modification corrects the Helpdesk e-mail address in the application package to read cdmrp.pa@amedd.army.mil.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-SIA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	25
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Synergistic Idea Award mechanism was first offered in FY06. Since that time, 718 Synergistic Idea Award proposals have been received and 58 have been recommended for funding. The Synergistic Idea Award supports collaborations between two independent investigators who address an innovative, high-risk, potentially high-reward breast cancer research question from synergistic and complementary perspectives. The Synergistic Idea Award is designed to promote new ideas and new collaborations. Proposals are not required to include preliminary data, but a rationale for the work must be provided. Proposals should have a high probability of revealing new avenues of investigation. The Synergistic Idea Award requires the submission of a single proposal that addresses a critical issue in breast cancer research. Proposals must clearly identify the synergy that will enable or greatly accelerate the evaluation of a single innovative hypothesis. The BCRP seeks proposals from all areas of laboratory clinical, behavioral, and epidemiological research. Multi-institutional and/or multidisciplinary proposals are encouraged but not required. Collaborators not from distinct disciplines must clearly explain why the proposed research is synergistic. Innovation, synergy, and impact are important aspects of the Synergistic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that is not innovative and will not be considered for funding under this award mechanism include: • Investigating the next logical step or incremental advancement of published data. • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. Synergy: Research combinations demonstrating synergy are those that will significantly advance a project beyond what would be possible through individual efforts. Contributions to the synergy of this mechanism are expected to be balanced between the two investigators unless otherwise justified. It should be clear that both investigators have an equal level of intellectual input into the proposed project. This award mechanism is designed to support completely new ideas, not ideas that are extensions of existing collaborative efforts. New collaborations are strongly encouraged but not required. If the investigators have a history of collaboration, then they must clearly demonstrate how the proposed research is a new synergistic effort. Examples of a collaboration that is not synergistic and will not be considered for funding under this award mechanism include: • Reagents supplied by one collaborator and molecular studies completed by the other collaborator. • Service function or core support providing laboratory investigations or statistical analyses. • Projects that can be accomplished in a single PI's laboratory. Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16802>

Department of Defense

Dept. of the Army -- USAMRAA

DoD Neurofibromatosis Investigator-Initiated Research Award Modification 2

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-IIRA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 11, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$3,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding. The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over today's approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3)

enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:• Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;• Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;• Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;• Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials. Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:• The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.• If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.• The collaborator must be at or above the level of Assistant Professor (or equivalent).• At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16780>

Department of Defense
Office of Naval Research
Naval Supply Systems Command
National Security Science and Engineering Faculty Fellowship (NSSEFF) Program
Modification 5

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	NPSBAA08-001
Opportunity Category:	Discretionary
Posted Date:	Jan 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Mar 28, 2008
Current Closing Date for Applications:	Mar 28, 2008

Archive Date:	Apr 27, 2008
Funding Instrument Type:	Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	
Estimated Total Program Funding:	
Award Ceiling:	
Award Floor:	
CFDA Number:	12.300 -- Basic and Applied Scientific Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Public and State controlled institutions of higher education
Private institutions of higher education

Description

The Naval Postgraduate School (NPS) will receive applications for the National Security Science and Engineering Faculty Fellowships (NSSEFF) Program. The Department of Defense (DoD), Office of the Director, Defense Research and Engineering (DDR&E) has established the NSSEFF program with the following objectives: provide extensive, long-term financial support to distinguished university faculty scientists and engineers to conduct unclassified, fundamental research on topics of interest to DoD; ensure that our nation has an active, long-term, well informed, and aggressive research and engineering portfolio that attracts creative and energetic scientists, engineers, and their students. The Fellowship is open to U.S. citizens whose earned Ph.D. was awarded within the past 25 years. Accredited, degree-granting educational institutions may nominate distinguished faculty scientists and engineers to receive National Security Science and Engineering Faculty Fellowships. The Fellows will be selected based on competitive evaluations of the scientific and technical merit of the nominees' white papers and proposals. It is anticipated that as many as 10 fellowships will be awarded each fiscal year. Each Fellow will receive up to \$3,000,000 in long-term financial support (up to \$600,000 per year for up to five (5) consecutive years) to conduct fundamental research on topics of interest to DoD. Fellows are expected to produce quantifiable research results over the five-year period of the grant. Fellows are also expected to participate in all NSSEFF activities. Although the intent for the fundamental research is to be unclassified, each Fellow must hold a Secret security clearance. The NSSEFF program will expose Fellows to classified information necessary to inform the objectives, approach, and conduct of their fundamental research. A current Secret security clearance is not required at the time of application. However, Fellows must be granted and maintain a final Secret clearance to receive program funding. Grants will be made to the Fellow's university in accordance with all applicable laws and

regulations, but the award is portable with the individual Fellow. The Fellows will be required to be full and active participants in all NSSEFF activities, provide annual reports of research progress and financial management to the Department, and brief DoD leadership in person at least once each year on their research progress and results. Research topics should be aligned with the Desired Capabilities S&T Investment Areas or the Enabling Technology Investment Areas or from the 2007 Director of Defense Research and Engineering (DDR&E) Strategic Plan. Before selecting research topic(s), a thorough reading the Strategic Plan is highly recommended. Additional details are available at: http://www.dod.mil/ddre/doc/Strategic_Plan_Final.pdf

Link to Full Announcement

[Link to All NPS BAA's](#)

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16422>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Synergistic Idea Award
Modification 2

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded). In addition, this modification corrects the Helpdesk e-mail address in the application package to read cdmrp.pa@amedd.army.mil.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-SIA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	25
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	

Award Floor:

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Synergistic Idea Award mechanism was first offered in FY06. Since that time, 718 Synergistic Idea Award proposals have been received and 58 have been recommended for funding. The Synergistic Idea Award supports collaborations between two independent investigators who address an innovative, high-risk, potentially high-reward breast cancer research question from synergistic and complementary perspectives. The Synergistic Idea Award is designed to promote new ideas and new collaborations. Proposals are not required to include preliminary data, but a rationale for the work must be provided. Proposals should have a high probability of revealing new avenues of investigation. The Synergistic Idea Award requires the submission of a single proposal that addresses a critical issue in breast cancer research. Proposals must clearly identify the synergy that will enable or greatly accelerate the evaluation of a single innovative hypothesis. The BCRP seeks proposals from all areas of laboratory clinical, behavioral, and epidemiological research. Multi-institutional and/or multidisciplinary proposals are encouraged but not required. Collaborators not from distinct disciplines must clearly explain why the proposed research is synergistic. Innovation, synergy, and impact are important aspects of the Synergistic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that is not innovative and will not be considered for funding under this award mechanism include: • Investigating the next logical step or incremental advancement of published data. • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. Synergy: Research combinations demonstrating synergy are those that will significantly advance a project beyond what would be possible through individual efforts. Contributions to the synergy of this mechanism are expected to be balanced between the two investigators unless otherwise justified. It should be clear that both investigators have an equal level of intellectual input into the proposed project. This award mechanism is designed to support completely new ideas, not ideas that are extensions of existing collaborative efforts. New collaborations are strongly encouraged but not required. If the investigators have a history of collaboration, then they must clearly demonstrate how the proposed research is a new synergistic effort. Examples of a collaboration that is not synergistic and will not be considered for funding under this award mechanism include: • Reagents supplied by one

collaborator and molecular studies completed by the other collaborator. • Service function or core support providing laboratory investigations or statistical analyses. • Projects that can be accomplished in a single PI's laboratory. Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16802>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Translational Research Partnership Modification 2

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile (Expanded).

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-TRP
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$2,500,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Translational Research Partnership Award was first offered in FY07 to support partnerships between clinicians and laboratory scientists to conduct translational research in ovarian cancer. During this time, 22 proposals were received for the Translational Research Partnership Award, and 5 were recommended for funding. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that accelerate the movement of promising ideas in ovarian cancer into clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in ovarian cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a laboratory scientist and the other must be a clinician, and it should be clear that both have had equal intellectual input into the design of the research project. At least one member of the partnership must have experience either in ovarian cancer research or ovarian cancer patient care. Historically Black College and Universities/Minority Institutions are encouraged to apply. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into the clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. Developing the research plan must involve a reciprocal flow of ideas and information within the partnership. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at (<http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals>). These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Translational Research Partnership Award does not support clinical trials, but may support correlative studies that are associated with an existing clinical trial and projects that develop clinical endpoints for clinical trials. Research projects may also include preclinical studies in animal models and human subjects and human anatomical substances. This award is intended to support both new and established scientists across a broad spectrum of disciplines in research projects that are likely to make a major impact on ovarian cancer. NEW FOR FY08 – The Translational Research Partnership award accepts proposals from all areas of research, but encourages research from these Areas of Encouragement:• Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. This award mechanism is not intended to support the study of new combinations of conventional ovarian cancer therapies. The use of

existing resources is encouraged, including libraries of compounds or probes, tissue repositories such as those managed by the Gynecologic Oncology Group, and other existing sets of tissue, blood, or images. Important aspects of the Translational Research Partnership Award are as follows:1. Partnership: The success of the project depends on the unique skills and contributions of each partner. • Optional Non-traditional Partnership (NEW FOR FY08): This award encourages a partnership between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional partnership is to leverage resources in the ovarian cancer research community. It is expected that in addition to providing intellectual input, the optional non-traditional partnership will contribute research resources (e.g., supplies, reagents, equipment, personnel) and/or financial resources.2. Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas in ovarian cancer into clinical applications.3. Preliminary Data: Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in ovarian cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16815>

Department of Defense
 Dept. of the Army -- USAMRAA
 DOD Prostate Cancer Synergistic Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-SIDA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$5,600,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research

and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Synergistic Idea Development Award mechanism was introduced in FY07. Since then, a total of 73 proposals have been received and 8 (representing 18 individual awards) have been recommended for funding. The Synergistic Idea Development Award supports innovative, high-risk/high-gain approaches to prostate cancer research involving two or three independent, faculty-level (or equivalent) PIs. These investigators should use synergistic and complementary perspectives to address a central problem or question in prostate cancer research. This award is designed to encourage and support both new and pre-existing partnerships. The overall goal of this award is to accelerate advances in prostate cancer research to support the PCRP vision of conquering prostate cancer. The Synergistic Idea Development Award requires that investigators jointly design a single project. However, each partner will be recognized as a PI, submit a separate proposal, and receive an individual award. The proposal must be supported by the unique expertise of each PI, and must clearly define the synergistic components that will facilitate and accelerate progress in a way that could not be accomplished through independent efforts. Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include clearly stated plans for interactions among all PIs and institutions involved. The plans must include ongoing communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional proposals must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. NEW FOR FY08: Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16878>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Clinical Trial Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-CTA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$2,700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Clinical Trial Award mechanism was introduced in FY01. Since then, 71 proposals have been received and 16 have been recommended for funding. The Clinical Trial Award supports rapid execution of Phase 0/I, Phase I, Phase I/II, or Phase II clinical trials with the potential to have a significant impact on prostate cancer prevention, detection, diagnosis, or treatment. Studies in a broad range of areas related to prostate cancer clinical management and care will be accepted under this mechanism, including but not limited to: • Evaluations of novel drugs, biologics, or devices • Survivorship • Diet • Quality of life • Psychosocial interventions • Behavioral studies Exploratory clinical trials (Phase 0) may be submitted, but they must be accompanied by a Phase I clinical trial (Phase 0/I). PIs must clearly specify in their proposals which type of clinical trial, Phase 0/I, Phase I, Phase I/II, or Phase II, is being proposed. Please refer to <http://www.clinicaltrials.gov/> for definitions and descriptions of each type of clinical trial. Each proposal must include only one clinical trial. PIs are encouraged to pursue correlative studies that accompany their trials. PIs conducting correlative studies must describe in detail the study aims, procedures or methods, and plans for data management and analysis, including an

appropriately powered statistical plan. It is expected that the intervention, drug, or device to be used in the proposed trial will be available in sufficient quantities and ready for clinical trials at the time that the award is made. Further, it is expected that the clinical trial will be initiated within 12 months of the award date. Note that Investigational New Drug (IND)/Investigational Device Exemption (IDE) approvals, if applicable, should be in process or completed before submission of an application to this mechanism. If IND/IDE approval is not received by April 30, 2009, the Government reserves the right to not fund the award. Funding from this award mechanism cannot be used for preclinical research studies.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16879>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Prostate Cancer Laboratory-Clinical Transition Award: Stage I Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-LCTAI
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$5,400,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

1. Overview The PCRP Laboratory-Clinical Transition Award: Stage I mechanism was introduced in FY07. Since then, 17 proposals have been received and 3 have been recommended for funding. The Laboratory-Clinical Transition Award: Stage I represents the first step of a three-step sequence to foster the bench-to-bedside transition of promising agents into the clinic to benefit prostate cancer patients. The Laboratory-Clinical Transition Award: Stage I supports goal- and product-driven preclinical studies of lead agents that have the potential to revolutionize the prevention, detection, or treatment of prostate cancer. The second step, the Laboratory-Clinical Transition Award: Stage II, will fund production and testing of current Good Manufacturing Practices (cGMP) agents before clinical trials. The Laboratory-Clinical Transition Award: Stage II, described briefly at the end of this section, will be offered in FY10 pending availability of funds. The third step, conduct of Phase I and Phase II clinical trials of the cGMP-produced agent, may be sponsored through the PCRP Clinical Trial Award, which is anticipated to be offered yearly pending availability of funds, or similar award mechanisms from other funding sources.

2. Laboratory-Clinical Transition Award: Stage I The Laboratory-Clinical Transition Award: Stage I is intended to fund PIs who lack support to conduct the preclinical studies needed to advance lead agents to human testing. The goal of this award is the generation of sufficient data to justify inclusion of lead agents into future clinical trials for the prevention, detection, or treatment of prostate cancer. For the purposes of the Laboratory-Clinical Transition Award: Stage I, lead agents are defined as biological or chemical therapeutics, imaging agents, or preventive agents that have potential clinical application to prostate cancer. Examples of lead agents include but are not limited to: novel chemotherapeutics, antibodies, viral particles, and contrast agents. PIs are expected to identify and have access to either one lead agent or a limited number of lead agents for optimization at the time of proposal submission. All Laboratory-Clinical Transition Award: Stage I proposals must include preliminary data relevant to the lead agent(s) under development. Preliminary data must provide information regarding target availability and distribution in human prostate cancer tissues and must support the relevance of the target for the prevention, detection, or treatment of human prostate cancer. Preliminary data must also support the efficacy of each agent in model systems. The National Cancer Institute has constructed developmental pathways for translational research (http://www.cancer.gov/images/trwg/Developmental-Pathway-Agent-Drug_Biologics.pdf) that may be useful for designing translational research studies for support under this mechanism. These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Laboratory-Clinical Transition Award: Stage I only supports research from the identification of a lead agent up to but not including cGMP production of the agent. This award may not be used to conduct clinical trials. Studies that may be funded under this award include, but are not limited to:

- Comparative activity/efficacy testing to define a single lead agent from a limited library of candidates. Such studies must be completed within 12 months of the start date of the award. If the studies are not completed within 12 months of award initiation, funding for the award may be terminated.
- Toxicology screening
- Drug metabolism, biodistribution, and pharmacokinetic assays
- Pharmacodynamic studies
- Radiation dosimetry
- Development and

validation of assays and reagents required to measure biological responses and molecular endpoints Studies that may NOT be funded under this award include, but are not limited to: • Target discovery • Drug screening • Development of devices • Development of serum- or tissue-based biomarkers for the primary diagnosis of disease • New combinations or formulations of conventional therapeutics Preclinical studies involving human subjects or specimens will be supported only if they are exempt under Title 32 of the Code of Federal Regulations Section 219.101(b)(4)(32 CFR 219.101(b)(4)) or qualify for expedited review under 32 CFR 219.110 or 21 CFR 56.1102. Studies that do not qualify for exempt status or expedited review will be administratively withdrawn and will not be funded. The preclinical drug development process may require resources beyond those available at a single laboratory or institution. As such, the PI must disclose any patents, issued or pending, and/or licenses, granted and/or pending, with respect to the lead agent(s) as well as any known patents that block the development of the lead agent(s). In the event that the project requires the use of a non-commercially available technology/material that is patented by a third party, the PI must provide documentation that the third party patent holder does not object to the PI's use of the patented technology/material. Since the ultimate goal of translational research is to obtain Investigational New Drug (IND) approvals on lead agents, PIs are expected to abide by US Food and Drug Administration (FDA) proposed and existing regulations governing the conduct of preliminary studies and the collection of data in support of an IND application (refer to http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm). Please note that the focus of the Laboratory-Clinical Transition Award: Stage I is to support the optimization of an identified lead agent up to but not including cGMP production of the agent. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. 3. Laboratory-Clinical Transition Award: Stage II The Laboratory-Clinical Transition Award: Stage II will facilitate and expedite the next stage of the bench-to-bedside transition of promising lead agents by funding: • Full-scale cGMP production of the agent for clinical trials. • Studies with the cGMP-produced agent (e.g., toxicology and pharmacology) to support an IND application (or equivalent) to the FDA or other regulatory agency. • Development of a clinical protocol for submission to the PCRP Clinical Trial Award or a clinical trial award mechanism from another funding source. Collaboration with the existing PCRP Clinical Consortium for protocol development will be encouraged but not required. All PIs funded by the Laboratory-Clinical Transition Award: Stage I who have viable lead agents are encouraged to compete for the Laboratory-Clinical Transition Award: Stage II, which is anticipated to be offered in FY10 pending receipt of appropriations. The Laboratory-Clinical Transition Award: Stage II will also be open to PIs who have not submitted to or been funded by the Laboratory-Clinical Transition Award: Stage I. Full guidance regarding the format and content of the Laboratory-Clinical Transition Award: Stage II proposal will be provided in the Program Announcement for the Laboratory-Clinical Transition Award: Stage II. Please note that there is no guarantee that funds will be available for the Laboratory-Clinical Transition Award: Stage II.

Link to Full Announcement

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Clinical Consortium Award Grant Modification 3

Description of Modification

The purpose of this modification is to clarify the performance period for the Coordinating Center. The Coordinating Center performance period is 5-years. See the revised Program Announcement for this clarification.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-CCA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 20, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	13
Estimated Total Program Funding:	\$25,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted

Description

General Information: The PCRP Clinical Consortium Award mechanism was introduced in FY05. Since then, 19 proposals have been received and 11 have been recommended for funding. Of these, 2 proposals were for the Coordinating Center, with one being funded, and 17 were for Clinical Research Sites, with 10 being funded. The Clinical Consortium Award does not provide funding for

research, but, rather, provides the support to develop the collaborations and resources necessary for the consortium to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) clinical trials of therapeutic agents or approaches for the management or treatment of prostate cancer. Trials that incorporate clinical validation of novel biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are strongly encouraged. The overarching goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market novel therapeutic interventions that will ultimately decrease the overall impact of the disease. PIs from both US and international institutions may apply. Submissions from institutions with enhanced access to patients from disproportionately affected populations are encouraged. It is expected that the consortium will achieve financial self-sufficiency during the award period such that consortium activities can continue after funding through this mechanism ends. The consortium will consist of approximately 12 Clinical Research Sites and one Coordinating Center. These participants will be jointly responsible for proposing, selecting, and conducting Phase II and Phase I/II clinical trials focused on prostate cancer therapeutic interventions. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16882>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Prostate Cancer Health Disparity Research Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-HDRA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	8
Estimated Total Program Funding:	\$3,200,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Health Disparity Research Award mechanism was introduced in FY01. Since then, 95 proposals have been received and 30 have been recommended for funding. The Health Disparity Research Award reflects the PCRP's commitment to resolving disparities in prostate cancer incidence, morbidity, and mortality by funding health disparity-focused projects by investigators at multiple points in their careers: • Transitioning Investigators: Mentored investigators transitioning into their first independent faculty position and establishing their own independent research programs. • Early-Career Investigators: Independent investigators in the early stages of their careers. • Established Investigators: Independent investigators at or above the Assistant Professor level or equivalent. Appropriate disparity focus areas include, but are not limited to: • Race and ethnicity, • Socioeconomic status, • Access to health care, • Insurance status, • Age, • Geography, and • Cultural beliefs. PIs who do not have either experience in prostate cancer research or a connection to, or effectiveness in working with, an affected population or community are strongly encouraged to include a collaborator (or collaborators) with the appropriate prostate cancer or health disparity research experience. Such experience may include: • Being a member of the affected population or community with a demonstrated commitment to the affected population or community; • Having experience working with the affected population or community; or • Having interactions with or an active membership in organizations such as the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, Patient Advocate Foundation National African American Outreach Program, or Prostate Health Education Network (PHEN). In addition, the proposal must explicitly state how the proposed research is related to a health disparity focus area in prostate cancer. This award may support research with laboratory animals and human biological substances, as well as research with human subjects that does not involve clinical trials. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16883>

DOD Prostate Cancer Health Disparity Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-HDTA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	6
Estimated Total Program Funding:	\$700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Health Disparity Training Award was introduced in FY01. Since then, 24 proposals have been received and 12 have been recommended for funding. The Health Disparity Training Award supports training opportunities focused on prostate cancer disparity for individuals in the early stages of their careers. The award funds research under the guidance of a mentor who is an experienced prostate cancer health disparity researcher. PIs may apply for predoctoral and postdoctoral traineeships through this award mechanism. Appropriate disparity focus areas can include, but are not limited to: • Race and ethnicity, • Socioeconomic status, • Access to health care, • Insurance status, • Age, • Geography, and • Cultural beliefs. The mentor must demonstrate a connection to, or effectiveness in working with, the affected population or community. Such connection(s) may include: • Being a member of the affected population or community with a demonstrated commitment to the affected population or community; • Having experience working with the affected population or community; or • Having interactions with and/or active membership in

organizations such as the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, Patient Advocate Foundation National African American Outreach Program, or Prostate Health Education Network (PHEN). The proposal must explicitly state how the proposed research is related to a health disparity focus area in prostate cancer. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer health disparity researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer health disparity research. All Health Disparity Training Award proposals are to be written with appropriate direction from the mentor and signed by the trainee as the PI and author of the proposal. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16884>

Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Career Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-CAR
Opportunity Category:	Discretionary
Posted Date:	Feb 25, 2008
Creation Date:	Feb 25, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	6
Estimated Total Program Funding:	\$3,300,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Career Development Award (NEW FOR FY08) is intended to support research training opportunities for investigators wishing to pursue an independent career in ovarian cancer research. This award supports individuals in the early stages of their careers by providing the opportunity to obtain the funding and experience necessary to pursue an independent career at the forefront of ovarian cancer research. Key elements of this award include:

- **Principal Investigator:** PIs may be research- or physician-scientists at either the postdoctoral or early-career level. Investigators from Historically Black Colleges and Universities/Minority Institutions are encouraged to apply.
- **Ovarian Cancer Mentorship:** A designated mentor is required. This mentor must be an established ovarian cancer researcher; have ovarian cancer funding (past and present); and have a record of ovarian cancer publications in peer reviewed journals. In addition, the mentor must demonstrate a commitment to developing and sustaining the PI's independent research career in ovarian cancer research.
- **Career Development:** The Career Development Plan should be prepared with guidance from the mentor. The proposal should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of ovarian cancer research. The plan should outline how the PI will be trained in ovarian cancer research. Because career development is the focus of this award, the institution must demonstrate a commitment to the PI through protected time: at least 50% for a research Postdoctoral Fellow PI and at least 25% for the Physician-Scientist PI or Early-Career PI.
- **Research Strategy:** Studies in all areas of ovarian cancer-focused research may be proposed for the Career Development Award; however, research from one of the three areas listed below is encouraged (NEW FOR FY08):
 - o Identification and characterization of early changes associated with ovarian cancer.
 - o Identification and characterization of ovarian cancer stem cells.
 - o The contribution of the stroma to the tumor microenvironment in ovarian cancer.Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. Clinical trials are not allowed under this award mechanism. The Career Development Award is a Phase I Award. All PIs funded by this award will be encouraged to compete for an independent Phase II award designed to sustain independent ovarian cancer researchers. It is anticipated that the Phase II award will be offered in FY11, pending availability of Federal funds for this program.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16943>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Neurofibromatosis Clinical Trial Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-CTA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$1,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Clinical Trial Award (CTA) mechanism was created in FY99. Since then, 18 Clinical Trial Award proposals have been received, and 3 have been recommended for funding. The NFRP Clinical Trial Award supports clinical research with the potential to have a major impact on the treatment and/or management of neurofibromatosis and/or Schwannomatosis. Funding from this award mechanism cannot be used for preclinical research studies. Clinical Trial Awards will support Phase 0, Phase I, and Phase II clinical trials (please refer to <http://www.clinicaltrials.gov> and www.fda.gov/cder/guidance/6384dft.htm for descriptions of each type of clinical trial). Applicants must clearly specify in their proposals which type of clinical trial is being proposed: Phase 0, Phase I, or Phase II. Each proposal should contain only one clinical trial with a distinct study design. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is

required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. If the trial is multi-institutional, applicants should include plans for communication and real-time data transfer between the collaborating institutions as well as how specimens and/or imaging products obtained during the study will be handled in the appropriate sections of the Clinical Protocol. An intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials as part of the Supporting Documentation. Important aspects of the Clinical Trial Award are as follows: • The proposal must include a named study coordinator who will guide the clinical protocol through Institutional Review Board (IRB), Human Subjects Research Review Board (HSRRB), and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. • IRB approvals should be in process or completed before submission of the proposal to the Clinical Trial Award mechanism. • The results of the clinical trial should have a clear and important impact. • The clinical trial must have clearly defined and appropriate endpoints. • The PI must demonstrate availability of and access to an appropriate patient population that will support a meaningful outcome for the study.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16779>

Department of Defense
 Dept. of the Army -- USAMRAA
 DoD Neurofibromatosis Investigator-Initiated Research Award Grant

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-IIRA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 11, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$3,000,000
Award Ceiling:	
Award Floor:	

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding. The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over today's approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3) enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:

- Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;
- Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;
- Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
- Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:

- The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.
- If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.
- The collaborator must be at or above the level of Assistant Professor (or equivalent).

At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16780>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Neurofibromatosis New Investigator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-NIA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$1,350,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP New Investigator Award mechanism (NIA) was created in FY99. Since then, 150 New Investigator Award proposals have been received, and 34 have been recommended for funding. The intent of the NFRP New Investigator Award is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Eligible Principal Investigators (PIs) must be at or below the level of Assistant Professor (or equivalent), must have received no more than \$300K in direct costs for NF research as a PI of a federally funded, non-mentored peer reviewed grant, and must have not received a NIA from any CDMRP program previously.

Experience in NF research is allowed, but not required. However, PIs with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. NIA proposals must include preliminary data relevant to NF and the proposed project. The FY08 NFRP encourages proposals that specifically address critical needs of the NF Community in the following areas: • Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; • Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; • Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; • Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials. Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborator and address the following requirements: • The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without their involvement. • If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history. • The collaborator must be at or above the level of Assistant Professor (or equivalent). • At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16781>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Neurofibromatosis Exploration – Hypothesis Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-EHDA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 05, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008

Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$350,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Exploration – Hypothesis Development Award (EHDA) mechanism is being offered for the first time in FY08. The NFRP Exploration – Hypothesis Development Award supports the initial exploration of innovative, untested, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or it should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. Some gaps in supporting rationale may exist due to a lack of available information. The presentation of preliminary data is encouraged, but not required. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b). Studies that do not qualify for exempt or expedited status during review at any level will be administratively withdrawn and will not be funded. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas: • Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; • Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; • Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; • Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Link to Full Announcement

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-IDA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	55
Estimated Total Program Funding:	\$31,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Idea Development Award mechanism was introduced in FY97. Since then, 4,330 proposals have been received and 831 have been recommended for funding. The Idea Development Award supports innovative, high-risk/high-gain approaches to prostate cancer research. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. NEW FOR FY08: Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Important aspects of the Idea Development Award are as follows: 1. Innovation: Innovative research may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the

responsibility of the PI to clearly and explicitly articulate how the proposed research is innovative. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this mechanism. 2. Impact: Research that has high impact will, if successful, significantly advance current methods and concepts for the prevention, detection, diagnosis, or treatment of human prostate cancer. It is the responsibility of the PI to clearly and explicitly articulate the potential impact the proposed research will have on human prostate cancer. 3. Preliminary Data: NEW FOR FY08: Submission of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Although groundbreaking research often involves a degree of risk due to unforeseen difficulties or results, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16804>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer New Investigator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-NIA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	23
Estimated Total Program Funding:	\$7,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP New Investigator Award mechanism was introduced in FY99. Since then, 1,678 proposals have been received and 365 have been recommended for funding. The New Investigator Award supports independent PIs in the early stages of their careers. The PCRP seeks PIs who have innovative, high-impact ideas or new technologies applicable to prostate cancer research, prevention, detection, diagnosis, or treatment. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Important aspects of the New Investigator Award are as follows: 1. Personnel: The PI and collaborator are emphasized in this award. The PI's record of accomplishment will be evaluated regarding his or her potential for contributing to the prostate cancer research field. The PI and collaborator together will be emphasized in peer review to determine whether their combined background and prostate cancer-related expertise demonstrate the ability to accomplish the proposed work. 2. Innovation: Innovative research may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the responsibility of the PI to clearly and explicitly articulate how the proposed research is innovative. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this mechanism. 3. Impact: Research that has high impact will, if successful, significantly advance current methods and concepts for the prevention, detection, diagnosis, or treatment of human prostate cancer. It is the responsibility of the PI to clearly and explicitly articulate the potential impact the proposed research will have on human prostate cancer. 4. Collaborator: Submission to this award mechanism requires a collaborator (or collaborators), appropriate to the proposal, who has experience in prostate cancer research, as demonstrated by a record of funding and publications in prostate cancer research. 5. Preliminary Data: To encourage submissions from PIs early in their careers, proposals are not required to have preliminary data. Although groundbreaking research often involves a degree of risk due to unforeseen difficulties or results, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16805>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Physician Research Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-PRTA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	8
Estimated Total Program Funding:	\$4,700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Physician Research Training Award was introduced in FY03. Since then, 82 proposals have been received and 32 have been recommended for funding. The Physician Research Training Award supports a mentored training experience to prepare physicians with clinical duties and/or responsibilities for a productive career in prostate cancer research. The PI must be in the last year of an accredited medical residency or medical fellowship program, or within the first 3 years following his or her appointment as an Instructor, Assistant Professor, or equivalent. A training program appropriate to the area of study, which may include coursework and seminars, that will provide the PI with experience in key areas such as statistics, bioethics, and/or relevant basic science disciplines, must be part of the application. This award requires the involvement of a designated mentor with an established research program in prostate cancer. Funds from this award are intended to provide aggressive protection, at least 40%, of the PI's time for research. The PI must demonstrate a commitment to a career in prostate cancer research and clinical practice. In addition, up to 50% of a key support person's salary may be provided by this award. Up to \$10,000 in funds per year from this award may be used for research supplies, equipment, and travel to

scientific/technical meetings. These funds may be used for research with laboratory animals and human biological substances, as well as research with human subjects that does not involve clinical trials. PIs may participate in clinical trials as part of their training for this award, but funding for the clinical trials must come from a source other than this award. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16807>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Innovator Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-INNOV
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$6,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Innovator Award was first offered in FY01. Since that time, 176 Innovator Award proposals have been received and 16 have been recommended for funding. The Innovator Award supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to, breast cancer. These individuals will have the most potential for future ground breaking achievements in breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could ultimately lead to the eradication of breast cancer. Individuals may be from diverse organizations including, but not limited to, academic institutions, advocacy groups, government agencies, the private sector, the media, and/or professional societies. Since the intent of the Innovator Award mechanism is to recognize creative and innovative individuals rather than projects, the central feature of the award is the innovative contribution that the recipient can make to the eradication of breast cancer. As such, an individual selected to submit a full proposal is required to submit an essay addressing his or her area(s) of focus and how he or she will use the award to pursue his or her most creative vision in breast cancer research. The primary criteria for making these awards will be an individual's past record of creativity, their promise for continued innovation in future work, and an indication of how this award will create and further innovative strategies to solve the breast cancer problem. Experience in breast cancer research is not required; however, the proposal must focus on breast cancer and it is expected that the recipient will commit a minimum of 50% of his or her full-time professional effort to breast cancer research during the tenure of this award.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16808>

Department of Defense
Dept. of the Army -- USAMRAA
DoD Prostate Cancer Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-PCTA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	

Expected Number of Awards: 31
Estimated Total Program Funding: \$3,400,000
Award Ceiling:
Award Floor:
CFDA Number: 12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Prostate Cancer Training Award was introduced in FY06. Since then, 271 proposals have been received and 118 have been recommended for funding. The Prostate Cancer Training Award supports training opportunities focused on prostate cancer research or patient care for individuals in the early stages of their careers. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer research. All Prostate Cancer Training Award proposals are to be written with appropriate direction from the mentor and signed by the trainee as the PI and author of the proposal. PIs may apply for predoctoral and postdoctoral traineeships through this award mechanism.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16809>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Impact Award Grant

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-08-BCRP-IMPT
Opportunity Category: Discretionary
Posted Date: Feb 07, 2008
Creation Date: Feb 07, 2008
Original Closing Date for Applications: May 07, 2008
Current Closing Date for Applications: May 07, 2008

Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Impact Award mechanism was first offered in FY07. Since that time, 86 Impact Awards proposals have been received and none have been recommended for funding. The Impact Award supports unique projects or ideas (from small- to large-scale) that possess strong potential to have an unprecedented impact in breast cancer. The most important aspect of this mechanism is the potential of the proposed work to have an extraordinarily high impact and contribute significantly to the goal of eradicating breast cancer. The potential impact may be scientific or clinical and may be near-term or long-term. The proposed work may be from any discipline or combination of disciplines and must be based on a solid overall research strategy. The BCRP seeks proposals from all areas of basic, translational, clinical, behavioral, and epidemiological research. The Impact Award mechanism particularly encourages proposals from underdeveloped and/or underexplored topic areas. Proposals are expected to present ideas that are above and beyond those that fit current award mechanisms offered by the BCRP.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16811>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-IDA
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 07, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$2,800,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Idea Development Award mechanism was offered in FY02 through FY06 to support innovative research in ovarian cancer. During this time, 616 proposals have been received and 51 OCRP Idea Development Awards have been made. The OCRP Idea Development Award supports high impact, innovative research that will drive the field forward. NEW FOR FY08 – This award seeks proposals from all areas of ovarian cancer research. However, for FY08, this award encourages proposals that address critical needs of the ovarian cancer community in the following areas: • Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. Important aspects of the Idea Development Award are as follows: 1. Impact: The proposed research should have a significant impact on the concepts or methods that drive the field of ovarian cancer research. The proposed research is expected to make original and important contributions to the goal of advancing ovarian cancer research and/or ovarian cancer patient care. 2. Innovation:

Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. Examples of research that are not innovative and that will not be considered for funding under this mechanism include: Exploring a previously tested hypothesis in a different cell line; using a published series of in vitro assays to further characterize a model system; and incorporating known biomarkers into in vitro or clinical models of ovarian cancer. 3. Preliminary Data: Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. 4. Proposals Involving Clinical Trials: If a proposal requests support for a clinical trial, the PI is required to submit a clinical protocol in addition to the proposal by the proposal receipt deadline. Such trials must have a clinical coordinator who has sufficient time dedicated to the project to carry out the record keeping, coordination, and/or other administrative duties the project entails. The protocol will be reviewed separately. Clinical trials must begin within 12 months of the award date. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) is required, additional time may be granted. However, preference will be given to proposals that have U.S. Food and Drug Administration (FDA) approval at the time the award is made. 5. Optional Non-traditional Collaboration (NEW FOR FY08): The FY08 OCRP Idea Development Award strongly supports collaborative research between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional collaboration is to increase the leveraging of resources in the ovarian cancer research community. The collaborator in this optional non-traditional collaboration must contribute at least 10% level of effort to the project (as reflected in the budget) and provide intellectual input and research resources (e.g., supplies, reagents, equipment, personnel), or intellectual input and financial resources. Collaborations that bring new perspectives from other disciplines or bring new investigators into the ovarian cancer field are also strongly encouraged. Consequently, if the PI does not have experience in ovarian cancer, then the collaborator must have ovarian cancer experience, as demonstrated through publications in the field, funding history, and/or patient care.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16813>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Translational Research Partnership Grant

This Program Announcement is modified to incorporate a new revised application package.
PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION

PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded).

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-TRP
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$2,500,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Translational Research Partnership Award was first offered in FY07 to support partnerships between clinicians and laboratory scientists to conduct translational research in ovarian cancer. During this time, 22 proposals were received for the Translational Research Partnership Award, and 5 were recommended for funding. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that accelerate the movement of promising ideas in ovarian cancer into clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in ovarian cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a laboratory scientist and the other must be a clinician, and

it should be clear that both have had equal intellectual input into the design of the research project. At least one member of the partnership must have experience either in ovarian cancer research or ovarian cancer patient care. Historically Black College and Universities/Minority Institutions are encouraged to apply. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into the clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. Developing the research plan must involve a reciprocal flow of ideas and information within the partnership. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at (<http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals>). These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Translational Research Partnership Award does not support clinical trials, but may support correlative studies that are associated with an existing clinical trial and projects that develop clinical endpoints for clinical trials. Research projects may also include preclinical studies in animal models and human subjects and human anatomical substances. This award is intended to support both new and established scientists across a broad spectrum of disciplines in research projects that are likely to make a major impact on ovarian cancer. NEW FOR FY08 – The Translational Research Partnership award accepts proposals from all areas of research, but encourages research from these Areas of Encouragement: • Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. This award mechanism is not intended to support the study of new combinations of conventional ovarian cancer therapies. The use of existing resources is encouraged, including libraries of compounds or probes, tissue repositories such as those managed by the Gynecologic Oncology Group, and other existing sets of tissue, blood, or images. Important aspects of the Translational Research Partnership Award are as follows: 1. Partnership: The success of the project depends on the unique skills and contributions of each partner. • Optional Non-traditional Partnership (NEW FOR FY08): This award encourages a partnership between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional partnership is to leverage resources in the ovarian cancer research community. It is expected that in addition to providing intellectual input, the optional non-traditional partnership will contribute research resources (e.g., supplies, reagents, equipment, personnel) and/or financial resources. 2. Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas in ovarian cancer into clinical applications. 3. Preliminary Data: Preliminary data to support

the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in ovarian cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16815>

Department of Defense
Air Force Office of Scientific Research
Research Interests of the Air Force Office of Scientific Research Modification 3

Description of Modification

This BAA has been superseded by AFOSR-BAA-2008-1.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	AFOSR-BAA-2007-1
Opportunity Category:	Discretionary
Posted Date:	Sep 30, 2006
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	This announcement is AFOSR BAA 2007-1 and supersedes AFOSR BAA 2006-1. This announcement is open-ended until revised and should be referenced on all responses.
Current Closing Date for Applications:	This announcement is AFOSR BAA 2007-1 and supersedes AFOSR BAA 2006-1. This announcement is open-ended until revised and should be referenced on all responses.
Archive Date:	Feb 07, 2008
Funding Instrument Type:	Cooperative Agreement Grant Procurement Contract
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	
Estimated Total Program Funding:	
Award Ceiling:	
Award Floor:	
CFDA Number:	12.800 -- Air Force Defense Research Sciences Program
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Additional Information on Eligibility:

All responsible, potential applicants from academia and industry are eligible to submit proposals. AFOSR particularly encourages proposals from small businesses, historically black colleges and universities, minority institutions and minority researchers. However, no portion of this BAA is set aside for a specific group.

Description

AFOSR plans, coordinates, and executes the Air Force Research Laboratory's (AFRL) basic research program in response to technical guidance from AFRL and requirements of the Air Force; fosters, supports, and conducts research within Air Force, university, and industry laboratories; and ensures transition of research results to support USAF needs. The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in three scientific directorates: Aerospace and Materials Sciences, Physics and Electronics, and Mathematics, Information and Life Sciences. If the Full Announcement Link is not available on this synopsis, the FULL ANNOUNCEMENT is available on the Grants.gov website by scrolling to the top of the synopsis page and clicking on the "FULL ANNOUNCEMENT" box surrounded by the dotted line.

Link to Full Announcement

[FULL ANNOUNCEMENT AFOSR-BAA-2007-1
http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opld=11104](http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opld=11104)

Department of Defense
Office of Naval Research
Naval Research Laboratory
NRL Wide Broad Agency Announcement BAA-07-01
Modification 4

Description of Modification

This opportunity is modified by revising topic BAA 57-07-03, Shipboard Electronic Warfare. The Surface Electronic Warfare Systems Branch (SEWS) is interested in design concepts that will incorporate advanced technology in the development and demonstration of a prototype Electronic Warfare (EW) system for shipboard application. NRL is looking to fund multiple proposals beginning FY09 under this BAA for prototype EW systems and or subsystems. An industry day to provide additional classified information will be held at NRL on 5 March 2008. Attendance will be limited to three representatives per company. NRL will request proposals based on white papers submitted in response to this BAA and received by 10 April 2008.

Names of persons attending and their security clearance need to be submitted to NRL by 27 February 2008. The POC for submitting visit requests and clearances is Ms. Helen Crosby, voice: 202-767-5931, fax: 202-404-7690, email: Helen.crosby@nrl.navy.mil. The revised topic as well as the complete BAA including proposal preparation instructions, technical points of contact for each topic, and evaluation criteria is available at <http://heron.nrl.navy.mil/contracts/0708baa/baa.htm>

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	NRLBAA-07-01
Opportunity Category:	Discretionary
Posted Date:	May 11, 2007
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Dec 31, 2008
Current Closing Date for Applications:	Dec 31, 2008
Archive Date:	Dec 31, 2009
Funding Instrument Type:	Grant
Category of Funding Activity:	Science and Technology and other Research and Development
CFDA Number:	12.300 -- Basic and Applied Scientific Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Others

Link to Full Announcement

[NRL Wide Broad Agency Announcement BAA-07-01](http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=13884)
<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=13884>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Era of Hope Scholar Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-EOHS
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant

Category of Funding Activity:	Cooperative Agreement Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Era of Hope Scholar Award mechanism was first offered in FY04. Since that time, 112 Era of Hope Scholar Award proposals have been received and 23 have been recommended for funding. The Era of Hope Scholar Award supports individuals who have high potential for innovation in breast cancer research early in their careers. Nominees for this award should be exceptionally talented, early-career scientists who have demonstrated that they are the "best and brightest" in their field(s) through extraordinary creativity, vision, and productivity. They also should exhibit strong potential for leadership in the breast cancer research community and be able to articulate a vision for the eradication of breast cancer. Individuals should challenge current dogma and demonstrate an ability to look beyond tradition and convention. The Era of Hope Scholar Award proposal must focus on the PI's record of creative and original accomplishments, potential for leadership in the breast cancer research community, and vision for eradicating breast cancer. These aspects of the proposal will receive greater emphasis in the review process than the proposed research project, although the proposed research project also will be considered. Experience in breast cancer research is not required; however, the proposal must focus on breast cancer research and the PI must commit at least 50% of his or her full-time professional effort during the award period to breast cancer research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16794>

DOD Breast Cancer Era of Hope Postdoctoral Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-EHPA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	14
Estimated Total Program Funding:	\$5,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Era of Hope Postdoctoral Award mechanism was first offered in FY06. Since that time, 44 Era of Hope Postdoctoral Award proposals have been received and 16 have been recommended for funding. The Era of Hope Postdoctoral Award supports exceptionally talented recent doctoral graduates who possess both the ambition and the ability to pursue highly innovative breast cancer research during their postdoctoral training. Research proposed for funding by the Era of Hope Postdoctoral Award mechanism should challenge current scientific dogma and demonstrate that the applicant has an ability to look beyond tradition and convention. Award recipients will be expected to challenge the status quo through creative, high-risk, potentially high-gain research that ultimately may lead to the eradication of breast cancer. Candidates for this award should exhibit a strong desire to pursue a career in breast cancer research. Candidates should provide evidence that they are the "best and brightest" among their peers. Proposals must provide evidence of the candidate's potential for success in pursuing innovative research based on his or her qualifications,

characteristics, achievements, and letters of recommendation. Under this award mechanism, the postdoctoral trainee is considered the Principal Investigator (PI) and, as such, should write the project narrative with appropriate direction from the mentor. While the PI is not required to have previous experience in breast cancer research, this research proposal must focus on breast cancer research. The mentor must possess the appropriate expertise in breast cancer, have current peer reviewed breast cancer funding, and clearly demonstrate a commitment to guiding the PI's research and training. The proposed research must be clearly outlined and the innovative nature of the planned research project and/or training must be explicitly stated. Proposals with a multidisciplinary research approach to breast cancer are highly encouraged but not required. The proposal should include information about the mentor's experience in conducting innovative research and how he or she intends to support the PI's innovative breast cancer research endeavors. Proposals involving clinical trials do not meet the intent of this award mechanism. Proposals must provide details on the suitability of the PI's overall training plan for attaining the goals of this mechanism. In addition, proposals must elaborate on the training environment in which the candidate will work and how it will facilitate the candidate's career development as an innovator at the forefront of breast cancer research.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16795>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Breast Cancer Clinical Translational Research Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-CTR
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	Jun 19, 2008
Current Closing Date for Applications:	Jun 19, 2008
Archive Date:	Jul 19, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$75,000,000
Award Ceiling:	
Award Floor:	

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Clinical Translational Research (CTR) Award mechanism was first introduced in FY97. Since that time, 216 Clinical Translational Research Award proposals have been received and 40 have been recommended for funding. The CTR Award is intended to promote substantial improvements over current approaches to breast cancer chemoprevention and therapy, including predictive biomarker studies that would better align treatment options with more specific breast cancer subtypes and/or may identify a new way to treat breast cancer patients. These awards are intended to support research projects that are likely to have a major impact on breast cancer by applying promising research findings to the treatment of patients with, or populations at risk for, breast cancer. Principal Investigators (PIs) may have originated projects in their laboratories that will form the basis for translational research leading to clinical trials to be conducted during this award period. Alternatively, PIs may leverage partnerships with industry (if the ability to conduct the required translational research and early phase clinical trial can be demonstrated). Proposals must include preliminary data and a solid rationale to support the feasibility of innovative translational research leading to a prospective clinical trial or study during the course of the award. Proposals also must include a clear experimental plan and a properly powered statistical plan to perform a prospective clinical trial. Investigators must demonstrate availability of and access to an appropriate patient population that will support a meaningful outcome for the study. Proposals addressing predictive biomarker studies must be supported by a previous, retrospective study and must include data validating the methods for the collection, storage, annotation, and analysis of human biological substances.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16799>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Idea Award Grant

Document Type:

Grants Notice

Funding Opportunity Number:	W81XWH-08-BCRP-IDEA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 06, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	60
Estimated Total Program Funding:	\$35,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The BCRP Idea Award mechanism was first offered in FY93. Since that time, 12,797 Idea Award proposals have been received and 1,809 have been recommended for funding. The Idea Award supports highly innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer. The BCRP seeks proposals from all areas of basic, translational, clinical, behavioral, and epidemiological research. The Idea Award is designed to promote new ideas; therefore, proposals need not include preliminary data. Innovation and Impact are the most important aspects of the Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that are not innovative, and will not be considered for funding under this mechanism include: • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. • Investigating the next logical step or incremental advancement of published data.

Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16800>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Synergistic Idea Award Grant

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded). In addition, this modification corrects the Helpdesk e-mail address in the application package to read cdmrp.pa@amedd.army.mil.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-SIA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	25
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Synergistic Idea Award mechanism was first offered in FY06. Since that time, 718 Synergistic Idea Award proposals have been received and 58 have been recommended for funding. The Synergistic Idea Award supports collaborations between two independent investigators who address an innovative, high-risk, potentially high-reward breast cancer research question from synergistic and complementary perspectives. The Synergistic Idea Award is designed to promote new ideas and new collaborations. Proposals are not required to include preliminary data, but a rationale for the work must be provided. Proposals should have a high probability of revealing new avenues of investigation. The Synergistic Idea Award requires the submission of a single proposal that addresses a critical issue in breast cancer research. Proposals must clearly identify the synergy that will enable or greatly accelerate the evaluation of a single innovative hypothesis. The BCRP seeks proposals from all areas of laboratory clinical, behavioral, and epidemiological research. Multi-institutional and/or multidisciplinary proposals are encouraged but not required. Collaborators not from distinct disciplines must clearly explain why the proposed research is synergistic. Innovation, synergy, and impact are important aspects of the Synergistic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that is not innovative and will not be considered for funding under this award mechanism include: • Investigating the next logical step or incremental advancement of published data. • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. Synergy: Research combinations demonstrating synergy are those that will significantly advance a project beyond what would be possible through individual efforts. Contributions to the synergy of this mechanism are expected to be balanced between the two investigators unless otherwise justified. It should be clear that both investigators have an equal level of intellectual input into the proposed project. This award mechanism is designed to support completely new ideas, not ideas that are extensions of existing collaborative efforts. New collaborations are strongly encouraged but not required. If the investigators have a history of collaboration, then they must clearly demonstrate how the proposed research is a new synergistic effort. Examples of a collaboration that is not synergistic and will not be considered for funding under this award mechanism include: • Reagents supplied by one collaborator and molecular studies completed by the other collaborator. • Service function or core support providing laboratory investigations or statistical analyses. • Projects that can be accomplished in a single PI's laboratory. Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16802>

Department of Defense

Dept. of the Army -- USAMRAA

DoD Neurofibromatosis Investigator-Initiated Research Award Modification 2

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-NFRP-IIRA
Opportunity Category:	Discretionary
Posted Date:	Feb 05, 2008
Creation Date:	Feb 11, 2008
Original Closing Date for Applications:	Apr 09, 2008
Current Closing Date for Applications:	Apr 09, 2008
Archive Date:	May 09, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	4
Estimated Total Program Funding:	\$3,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding. The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over today's approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3)

enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:

- Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;
- Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;
- Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
- Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.

Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:

- The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.
- If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.
- The collaborator must be at or above the level of Assistant Professor (or equivalent).
- At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposal's budget.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16780>

Department of Defense
Office of Naval Research
Naval Supply Systems Command
National Security Science and Engineering Faculty Fellowship (NSSEFF) Program
Modification 5

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	NPSBAA08-001
Opportunity Category:	Discretionary
Posted Date:	Jan 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Mar 28, 2008
Current Closing Date for Applications:	Mar 28, 2008

Archive Date:	Apr 27, 2008
Funding Instrument Type:	Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	
Estimated Total Program Funding:	
Award Ceiling:	
Award Floor:	
CFDA Number:	12.300 -- Basic and Applied Scientific Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Public and State controlled institutions of higher education
Private institutions of higher education

Description

The Naval Postgraduate School (NPS) will receive applications for the National Security Science and Engineering Faculty Fellowships (NSSEFF) Program. The Department of Defense (DoD), Office of the Director, Defense Research and Engineering (DDR&E) has established the NSSEFF program with the following objectives: provide extensive, long-term financial support to distinguished university faculty scientists and engineers to conduct unclassified, fundamental research on topics of interest to DoD; ensure that our nation has an active, long-term, well informed, and aggressive research and engineering portfolio that attracts creative and energetic scientists, engineers, and their students. The Fellowship is open to U.S. citizens whose earned Ph.D. was awarded within the past 25 years. Accredited, degree-granting educational institutions may nominate distinguished faculty scientists and engineers to receive National Security Science and Engineering Faculty Fellowships. The Fellows will be selected based on competitive evaluations of the scientific and technical merit of the nominees' white papers and proposals. It is anticipated that as many as 10 fellowships will be awarded each fiscal year. Each Fellow will receive up to \$3,000,000 in long-term financial support (up to \$600,000 per year for up to five (5) consecutive years) to conduct fundamental research on topics of interest to DoD. Fellows are expected to produce quantifiable research results over the five-year period of the grant. Fellows are also expected to participate in all NSSEFF activities. Although the intent for the fundamental research is to be unclassified, each Fellow must hold a Secret security clearance. The NSSEFF program will expose Fellows to classified information necessary to inform the objectives, approach, and conduct of their fundamental research. A current Secret security clearance is not required at the time of application. However, Fellows must be granted and maintain a final Secret clearance to receive program funding. Grants will be made to the Fellow's university in accordance with all applicable laws and

regulations, but the award is portable with the individual Fellow. The Fellows will be required to be full and active participants in all NSSEFF activities, provide annual reports of research progress and financial management to the Department, and brief DoD leadership in person at least once each year on their research progress and results. Research topics should be aligned with the Desired Capabilities S&T Investment Areas or the Enabling Technology Investment Areas or from the 2007 Director of Defense Research and Engineering (DDR&E) Strategic Plan. Before selecting research topic(s), a thorough reading the Strategic Plan is highly recommended. Additional details are available at: http://www.dod.mil/ddre/doc/Strategic_Plan_Final.pdf

Link to Full Announcement

[Link to All NPS BAA's](#)

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16422>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Breast Cancer Synergistic Idea Award
Modification 2

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile(Expanded). In addition, this modification corrects the Helpdesk e-mail address in the application package to read cdmrp.pa@amedd.army.mil.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-BCRP-SIA
Opportunity Category:	Discretionary
Posted Date:	Feb 06, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	May 07, 2008
Current Closing Date for Applications:	May 07, 2008
Archive Date:	Jun 06, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	25
Estimated Total Program Funding:	\$15,000,000
Award Ceiling:	

Award Floor:

CFDA Number:

12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The Breast Cancer Research Program (BCRP) Synergistic Idea Award mechanism was first offered in FY06. Since that time, 718 Synergistic Idea Award proposals have been received and 58 have been recommended for funding. The Synergistic Idea Award supports collaborations between two independent investigators who address an innovative, high-risk, potentially high-reward breast cancer research question from synergistic and complementary perspectives. The Synergistic Idea Award is designed to promote new ideas and new collaborations. Proposals are not required to include preliminary data, but a rationale for the work must be provided. Proposals should have a high probability of revealing new avenues of investigation. The Synergistic Idea Award requires the submission of a single proposal that addresses a critical issue in breast cancer research. Proposals must clearly identify the synergy that will enable or greatly accelerate the evaluation of a single innovative hypothesis. The BCRP seeks proposals from all areas of laboratory clinical, behavioral, and epidemiological research. Multi-institutional and/or multidisciplinary proposals are encouraged but not required. Collaborators not from distinct disciplines must clearly explain why the proposed research is synergistic. Innovation, synergy, and impact are important aspects of the Synergistic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Examples of research that is not innovative and will not be considered for funding under this award mechanism include: • Investigating the next logical step or incremental advancement of published data. • Exploring a previously tested hypothesis in a different cell line or in a new population. • Using a published series of in vitro assays to further characterize a model system. • Incorporating known biomarkers into in vitro or clinical models of breast cancer. Synergy: Research combinations demonstrating synergy are those that will significantly advance a project beyond what would be possible through individual efforts. Contributions to the synergy of this mechanism are expected to be balanced between the two investigators unless otherwise justified. It should be clear that both investigators have an equal level of intellectual input into the proposed project. This award mechanism is designed to support completely new ideas, not ideas that are extensions of existing collaborative efforts. New collaborations are strongly encouraged but not required. If the investigators have a history of collaboration, then they must clearly demonstrate how the proposed research is a new synergistic effort. Examples of a collaboration that is not synergistic and will not be considered for funding under this award mechanism include: • Reagents supplied by one

collaborator and molecular studies completed by the other collaborator. • Service function or core support providing laboratory investigations or statistical analyses. • Projects that can be accomplished in a single PI's laboratory. Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16802>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Translational Research Partnership Modification 2

This Program Announcement is modified to incorporate a new revised application package. PLEASE NOTE THAT THIS APPLICATION PACKAGE REPLACES THE APPLICATION PACKAGE IN ORIGINAL PROGRAM ANNOUNCEMENT. FAILURE TO UPLOAD THIS APPLICATION PACKAGE MAY RESULT IN REJECTION OF YOUR APPLICATION SUBMISSION IN GRANTS.GOV. Specifically this new application package replaces the Research and Related Senior/Key Person Profile with the Research and Related Senior/Key Person Profile (Expanded).

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-TRP
Opportunity Category:	Discretionary
Posted Date:	Feb 07, 2008
Creation Date:	Feb 13, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	2
Estimated Total Program Funding:	\$2,500,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Translational Research Partnership Award was first offered in FY07 to support partnerships between clinicians and laboratory scientists to conduct translational research in ovarian cancer. During this time, 22 proposals were received for the Translational Research Partnership Award, and 5 were recommended for funding. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that accelerate the movement of promising ideas in ovarian cancer into clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in ovarian cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a laboratory scientist and the other must be a clinician, and it should be clear that both have had equal intellectual input into the design of the research project. At least one member of the partnership must have experience either in ovarian cancer research or ovarian cancer patient care. Historically Black College and Universities/Minority Institutions are encouraged to apply. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into the clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. Developing the research plan must involve a reciprocal flow of ideas and information within the partnership. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at (<http://www.cancer.gov/aboutnci/trwg/Pathways-to-Clinical-Goals>). These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Translational Research Partnership Award does not support clinical trials, but may support correlative studies that are associated with an existing clinical trial and projects that develop clinical endpoints for clinical trials. Research projects may also include preclinical studies in animal models and human subjects and human anatomical substances. This award is intended to support both new and established scientists across a broad spectrum of disciplines in research projects that are likely to make a major impact on ovarian cancer. NEW FOR FY08 – The Translational Research Partnership award accepts proposals from all areas of research, but encourages research from these Areas of Encouragement:• Identification and characterization of early changes associated with ovarian cancer. • Identification and characterization of ovarian cancer stem cells. • The contribution of the stroma to the tumor microenvironment in ovarian cancer. Proposals addressing one of these three Areas of Encouragement will be given primary consideration. This award mechanism is not intended to support the study of new combinations of conventional ovarian cancer therapies. The use of

existing resources is encouraged, including libraries of compounds or probes, tissue repositories such as those managed by the Gynecologic Oncology Group, and other existing sets of tissue, blood, or images. Important aspects of the Translational Research Partnership Award are as follows:1. Partnership: The success of the project depends on the unique skills and contributions of each partner. • Optional Non-traditional Partnership (NEW FOR FY08): This award encourages a partnership between an academic institution/government agency and a biotechnology/pharmaceutical company, or between an academic institution/government agency and a foundation, or between a biotechnology/pharmaceutical company and a foundation. The intent of this optional non-traditional partnership is to leverage resources in the ovarian cancer research community. It is expected that in addition to providing intellectual input, the optional non-traditional partnership will contribute research resources (e.g., supplies, reagents, equipment, personnel) and/or financial resources.2. Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas in ovarian cancer into clinical applications.3. Preliminary Data: Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in ovarian cancer.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16815>

Department of Defense

Dept. of the Army -- USAMRAA

DOD Prostate Cancer Synergistic Idea Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-SIDA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jun 12, 2008
Current Closing Date for Applications:	Jun 12, 2008
Archive Date:	Jul 12, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$5,600,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research

and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Synergistic Idea Development Award mechanism was introduced in FY07. Since then, a total of 73 proposals have been received and 8 (representing 18 individual awards) have been recommended for funding. The Synergistic Idea Development Award supports innovative, high-risk/high-gain approaches to prostate cancer research involving two or three independent, faculty-level (or equivalent) PIs. These investigators should use synergistic and complementary perspectives to address a central problem or question in prostate cancer research. This award is designed to encourage and support both new and pre-existing partnerships. The overall goal of this award is to accelerate advances in prostate cancer research to support the PCRP vision of conquering prostate cancer. The Synergistic Idea Development Award requires that investigators jointly design a single project. However, each partner will be recognized as a PI, submit a separate proposal, and receive an individual award. The proposal must be supported by the unique expertise of each PI, and must clearly define the synergistic components that will facilitate and accelerate progress in a way that could not be accomplished through independent efforts. Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include clearly stated plans for interactions among all PIs and institutions involved. The plans must include ongoing communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional proposals must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. The PCRP seeks proposals from all areas of basic, preclinical, behavioral, and epidemiological research. NEW FOR FY08: Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16878>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Clinical Trial Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-CTA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	3
Estimated Total Program Funding:	\$2,700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Clinical Trial Award mechanism was introduced in FY01. Since then, 71 proposals have been received and 16 have been recommended for funding. The Clinical Trial Award supports rapid execution of Phase 0/I, Phase I, Phase I/II, or Phase II clinical trials with the potential to have a significant impact on prostate cancer prevention, detection, diagnosis, or treatment. Studies in a broad range of areas related to prostate cancer clinical management and care will be accepted under this mechanism, including but not limited to: • Evaluations of novel drugs, biologics, or devices • Survivorship • Diet • Quality of life • Psychosocial interventions • Behavioral studies Exploratory clinical trials (Phase 0) may be submitted, but they must be accompanied by a Phase I clinical trial (Phase 0/I). PIs must clearly specify in their proposals which type of clinical trial, Phase 0/I, Phase I, Phase I/II, or Phase II, is being proposed. Please refer to <http://www.clinicaltrials.gov/> for definitions and descriptions of each type of clinical trial. Each proposal must include only one clinical trial. PIs are encouraged to pursue correlative studies that accompany their trials. PIs conducting correlative studies must describe in detail the study aims, procedures or methods, and plans for data management and analysis, including an

appropriately powered statistical plan. It is expected that the intervention, drug, or device to be used in the proposed trial will be available in sufficient quantities and ready for clinical trials at the time that the award is made. Further, it is expected that the clinical trial will be initiated within 12 months of the award date. Note that Investigational New Drug (IND)/Investigational Device Exemption (IDE) approvals, if applicable, should be in process or completed before submission of an application to this mechanism. If IND/IDE approval is not received by April 30, 2009, the Government reserves the right to not fund the award. Funding from this award mechanism cannot be used for preclinical research studies.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16879>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Laboratory-Clinical Transition Award: Stage I Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-LCTAI
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	5
Estimated Total Program Funding:	\$5,400,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

1. Overview The PCRP Laboratory-Clinical Transition Award: Stage I mechanism was introduced in FY07. Since then, 17 proposals have been received and 3 have been recommended for funding. The Laboratory-Clinical Transition Award: Stage I represents the first step of a three-step sequence to foster the bench-to-bedside transition of promising agents into the clinic to benefit prostate cancer patients. The Laboratory-Clinical Transition Award: Stage I supports goal- and product-driven preclinical studies of lead agents that have the potential to revolutionize the prevention, detection, or treatment of prostate cancer. The second step, the Laboratory-Clinical Transition Award: Stage II, will fund production and testing of current Good Manufacturing Practices (cGMP) agents before clinical trials. The Laboratory-Clinical Transition Award: Stage II, described briefly at the end of this section, will be offered in FY10 pending availability of funds. The third step, conduct of Phase I and Phase II clinical trials of the cGMP-produced agent, may be sponsored through the PCRP Clinical Trial Award, which is anticipated to be offered yearly pending availability of funds, or similar award mechanisms from other funding sources.

2. Laboratory-Clinical Transition Award: Stage I The Laboratory-Clinical Transition Award: Stage I is intended to fund PIs who lack support to conduct the preclinical studies needed to advance lead agents to human testing. The goal of this award is the generation of sufficient data to justify inclusion of lead agents into future clinical trials for the prevention, detection, or treatment of prostate cancer. For the purposes of the Laboratory-Clinical Transition Award: Stage I, lead agents are defined as biological or chemical therapeutics, imaging agents, or preventive agents that have potential clinical application to prostate cancer. Examples of lead agents include but are not limited to: novel chemotherapeutics, antibodies, viral particles, and contrast agents. PIs are expected to identify and have access to either one lead agent or a limited number of lead agents for optimization at the time of proposal submission. All Laboratory-Clinical Transition Award: Stage I proposals must include preliminary data relevant to the lead agent(s) under development. Preliminary data must provide information regarding target availability and distribution in human prostate cancer tissues and must support the relevance of the target for the prevention, detection, or treatment of human prostate cancer. Preliminary data must also support the efficacy of each agent in model systems. The National Cancer Institute has constructed developmental pathways for translational research (http://www.cancer.gov/images/trwg/Developmental-Pathway-Agent-Drug_Biologics.pdf) that may be useful for designing translational research studies for support under this mechanism. These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials. Please be aware that the Laboratory-Clinical Transition Award: Stage I only supports research from the identification of a lead agent up to but not including cGMP production of the agent. This award may not be used to conduct clinical trials. Studies that may be funded under this award include, but are not limited to:

- Comparative activity/efficacy testing to define a single lead agent from a limited library of candidates. Such studies must be completed within 12 months of the start date of the award. If the studies are not completed within 12 months of award initiation, funding for the award may be terminated.
- Toxicology screening
- Drug metabolism, biodistribution, and pharmacokinetic assays
- Pharmacodynamic studies
- Radiation dosimetry
- Development and

validation of assays and reagents required to measure biological responses and molecular endpoints. Studies that may NOT be funded under this award include, but are not limited to:

- Target discovery
- Drug screening
- Development of devices
- Development of serum- or tissue-based biomarkers for the primary diagnosis of disease
- New combinations or formulations of conventional therapeutics

Preclinical studies involving human subjects or specimens will be supported only if they are exempt under Title 32 of the Code of Federal Regulations Section 219.101(b)(4) (32 CFR 219.101(b)(4)) or qualify for expedited review under 32 CFR 219.110 or 21 CFR 56.1102. Studies that do not qualify for exempt status or expedited review will be administratively withdrawn and will not be funded. The preclinical drug development process may require resources beyond those available at a single laboratory or institution. As such, the PI must disclose any patents, issued or pending, and/or licenses, granted and/or pending, with respect to the lead agent(s) as well as any known patents that block the development of the lead agent(s). In the event that the project requires the use of a non-commercially available technology/material that is patented by a third party, the PI must provide documentation that the third party patent holder does not object to the PI's use of the patented technology/material. Since the ultimate goal of translational research is to obtain Investigational New Drug (IND) approvals on lead agents, PIs are expected to abide by US Food and Drug Administration (FDA) proposed and existing regulations governing the conduct of preliminary studies and the collection of data in support of an IND application (refer to http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm). Please note that the focus of the Laboratory-Clinical Transition Award: Stage I is to support the optimization of an identified lead agent up to but not including cGMP production of the agent. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism.

3. Laboratory-Clinical Transition Award: Stage II

The Laboratory-Clinical Transition Award: Stage II will facilitate and expedite the next stage of the bench-to-bedside transition of promising lead agents by funding:

- Full-scale cGMP production of the agent for clinical trials.
- Studies with the cGMP-produced agent (e.g., toxicology and pharmacology) to support an IND application (or equivalent) to the FDA or other regulatory agency.
- Development of a clinical protocol for submission to the PCRP Clinical Trial Award or a clinical trial award mechanism from another funding source.

Collaboration with the existing PCRP Clinical Consortium for protocol development will be encouraged but not required. All PIs funded by the Laboratory-Clinical Transition Award: Stage I who have viable lead agents are encouraged to compete for the Laboratory-Clinical Transition Award: Stage II, which is anticipated to be offered in FY10 pending receipt of appropriations. The Laboratory-Clinical Transition Award: Stage II will also be open to PIs who have not submitted to or been funded by the Laboratory-Clinical Transition Award: Stage I. Full guidance regarding the format and content of the Laboratory-Clinical Transition Award: Stage II proposal will be provided in the Program Announcement for the Laboratory-Clinical Transition Award: Stage II. Please note that there is no guarantee that funds will be available for the Laboratory-Clinical Transition Award: Stage II.

Link to Full Announcement

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Clinical Consortium Award Grant Modification 3

Description of Modification

The purpose of this modification is to clarify the performance period for the Coordinating Center. The Coordinating Center performance period is 5-years. See the revised Program Announcement for this clarification.

Document Type:	Modification to Previous Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-CCA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 20, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	13
Estimated Total Program Funding:	\$25,000,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted

Description

General Information: The PCRP Clinical Consortium Award mechanism was introduced in FY05. Since then, 19 proposals have been received and 11 have been recommended for funding. Of these, 2 proposals were for the Coordinating Center, with one being funded, and 17 were for Clinical Research Sites, with 10 being funded. The Clinical Consortium Award does not provide funding for

research, but, rather, provides the support to develop the collaborations and resources necessary for the consortium to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) clinical trials of therapeutic agents or approaches for the management or treatment of prostate cancer. Trials that incorporate clinical validation of novel biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are strongly encouraged. The overarching goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market novel therapeutic interventions that will ultimately decrease the overall impact of the disease. PIs from both US and international institutions may apply. Submissions from institutions with enhanced access to patients from disproportionately affected populations are encouraged. It is expected that the consortium will achieve financial self-sufficiency during the award period such that consortium activities can continue after funding through this mechanism ends. The consortium will consist of approximately 12 Clinical Research Sites and one Coordinating Center. These participants will be jointly responsible for proposing, selecting, and conducting Phase II and Phase I/II clinical trials focused on prostate cancer therapeutic interventions. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16882>

Department of Defense
Dept. of the Army -- USAMRAA
DOD Prostate Cancer Health Disparity Research Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-HDRA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Grant Cooperative Agreement
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	8
Estimated Total Program Funding:	\$3,200,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development

Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Health Disparity Research Award mechanism was introduced in FY01. Since then, 95 proposals have been received and 30 have been recommended for funding. The Health Disparity Research Award reflects the PCRP's commitment to resolving disparities in prostate cancer incidence, morbidity, and mortality by funding health disparity-focused projects by investigators at multiple points in their careers: • Transitioning Investigators: Mentored investigators transitioning into their first independent faculty position and establishing their own independent research programs. • Early-Career Investigators: Independent investigators in the early stages of their careers. • Established Investigators: Independent investigators at or above the Assistant Professor level or equivalent. Appropriate disparity focus areas include, but are not limited to: • Race and ethnicity, • Socioeconomic status, • Access to health care, • Insurance status, • Age, • Geography, and • Cultural beliefs. PIs who do not have either experience in prostate cancer research or a connection to, or effectiveness in working with, an affected population or community are strongly encouraged to include a collaborator (or collaborators) with the appropriate prostate cancer or health disparity research experience. Such experience may include: • Being a member of the affected population or community with a demonstrated commitment to the affected population or community; • Having experience working with the affected population or community; or • Having interactions with or an active membership in organizations such as the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, Patient Advocate Foundation National African American Outreach Program, or Prostate Health Education Network (PHEN). In addition, the proposal must explicitly state how the proposed research is related to a health disparity focus area in prostate cancer. This award may support research with laboratory animals and human biological substances, as well as research with human subjects that does not involve clinical trials. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16883>

DOD Prostate Cancer Health Disparity Training Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-PCRP-HDTA
Opportunity Category:	Discretionary
Posted Date:	Feb 15, 2008
Creation Date:	Feb 15, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	6
Estimated Total Program Funding:	\$700,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The PCRP Health Disparity Training Award was introduced in FY01. Since then, 24 proposals have been received and 12 have been recommended for funding. The Health Disparity Training Award supports training opportunities focused on prostate cancer disparity for individuals in the early stages of their careers. The award funds research under the guidance of a mentor who is an experienced prostate cancer health disparity researcher. PIs may apply for predoctoral and postdoctoral traineeships through this award mechanism. Appropriate disparity focus areas can include, but are not limited to: • Race and ethnicity, • Socioeconomic status, • Access to health care, • Insurance status, • Age, • Geography, and • Cultural beliefs. The mentor must demonstrate a connection to, or effectiveness in working with, the affected population or community. Such connection(s) may include: • Being a member of the affected population or community with a demonstrated commitment to the affected population or community; • Having experience working with the affected population or community; or • Having interactions with and/or active membership in

organizations such as the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, Patient Advocate Foundation National African American Outreach Program, or Prostate Health Education Network (PHEN). The proposal must explicitly state how the proposed research is related to a health disparity focus area in prostate cancer. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer health disparity researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer health disparity research. All Health Disparity Training Award proposals are to be written with appropriate direction from the mentor and signed by the trainee as the PI and author of the proposal. See the Program Announcement for the full Funding Opportunity Description.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&oppld=16884>

Dept. of the Army -- USAMRAA
DOD Ovarian Cancer Career Development Award Grant

Document Type:	Grants Notice
Funding Opportunity Number:	W81XWH-08-OCRP-CAR
Opportunity Category:	Discretionary
Posted Date:	Feb 25, 2008
Creation Date:	Feb 25, 2008
Original Closing Date for Applications:	Jul 02, 2008
Current Closing Date for Applications:	Jul 02, 2008
Archive Date:	Aug 01, 2008
Funding Instrument Type:	Cooperative Agreement Grant
Category of Funding Activity:	Science and Technology and other Research and Development
Category Explanation:	
Expected Number of Awards:	6
Estimated Total Program Funding:	\$3,300,000
Award Ceiling:	
Award Floor:	
CFDA Number:	12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

The OCRP Career Development Award (NEW FOR FY08) is intended to support research training opportunities for investigators wishing to pursue an independent career in ovarian cancer research. This award supports individuals in the early stages of their careers by providing the opportunity to obtain the funding and experience necessary to pursue an independent career at the forefront of ovarian cancer research. Key elements of this award include:

- **Principal Investigator:** PIs may be research- or physician-scientists at either the postdoctoral or early-career level. Investigators from Historically Black Colleges and Universities/Minority Institutions are encouraged to apply.
- **Ovarian Cancer Mentorship:** A designated mentor is required. This mentor must be an established ovarian cancer researcher; have ovarian cancer funding (past and present); and have a record of ovarian cancer publications in peer reviewed journals. In addition, the mentor must demonstrate a commitment to developing and sustaining the PI's independent research career in ovarian cancer research.
- **Career Development:** The Career Development Plan should be prepared with guidance from the mentor. The proposal should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of ovarian cancer research. The plan should outline how the PI will be trained in ovarian cancer research. Because career development is the focus of this award, the institution must demonstrate a commitment to the PI through protected time: at least 50% for a research Postdoctoral Fellow PI and at least 25% for the Physician-Scientist PI or Early-Career PI.
- **Research Strategy:** Studies in all areas of ovarian cancer-focused research may be proposed for the Career Development Award; however, research from one of the three areas listed below is encouraged (NEW FOR FY08):
 - o Identification and characterization of early changes associated with ovarian cancer.
 - o Identification and characterization of ovarian cancer stem cells.
 - o The contribution of the stroma to the tumor microenvironment in ovarian cancer.Preliminary data relevant to the proposed project, but not necessarily in ovarian cancer, are required. Clinical trials are not allowed under this award mechanism. The Career Development Award is a Phase I Award. All PIs funded by this award will be encouraged to compete for an independent Phase II award designed to sustain independent ovarian cancer researchers. It is anticipated that the Phase II award will be offered in FY11, pending availability of Federal funds for this program.

Link to Full Announcement

<http://www.grants.gov/search/search.do?&mode=VIEW&flag2006=true&opId=16943>